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One of the most critical aspects of G Protein Coupled Receptors (GPCRs) regulation 
is their rapid and acute desensitization following agonist stimulation. Phosphorylation of 
these receptors by GPCR kinases (GRK) is a major mechanism of desensitization. 
Considerable evidence from studies of rhodopsin kinase and GRK2 suggests there is an 
allosteric docking site for the receptor distinct from the GRK catalytic site. While the 
agonist-activated GPCR appears crucial for GRK activation, the molecular details of this 
interaction remain unclear. Recent studies suggested an important role for the N- and C-
termini and domains in the small lobe of the kinase domain in allosteric activation; however, 
neither the mechanism of action of that site nor the RH domain contributions have been 
elucidated. To search for the allosteric site, we first indentified evolutionarily conserved 
sites within the RH and kinase domains presumably deterministic of protein function 
employing evolutionary trace (ET) methodology and crystal structures of GRK6. Focusing 
on a conserved cluster centered on helices 3, 9, and 10 in the RH domain, key residues of 
GRK5 and 6 were targeted for mutagenesis and functional assays. We found that a number 
of double mutations within helices 3, 9, and 10 and the N-terminus markedly reduced (50-
90%) the constitutive phosphorylation of the β-2 Adrenergic Receptor (β2AR) in intact cells 
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and phosphorylation of light-activated rhodopsin (Rho*) in vitro as compared to wild type 
(WT) GRK5 or 6. Based on these results, we designed peptide mimetics of GRK5 helix 9 
both computationally and through chemical modifications with the goal of both confirming 
the importance of helix 9 and developing a useful inhibitor to disrupt the GPCR-GRK 
interaction. Several peptides were found to block Rho* phosphorylation by GRK5 including 
the native helix 9 sequence, Peptide Builder designed-peptide preserving only the key ET 
residues, and chemically locked helices. Most peptidomimetics showed inhibition of GRK5 
activity greater than 80 % with an IC50 of ~ 30 µM. Alanine scanning of helix 9 has further 
revealed both essential and non-essential residues for inhibition. Importantly, substitution of 
Arg 169 by an alanine in the native helix 9-based peptide gave an almost complete inhibition 
at 30 µM with an IC50 of ~ 10 µM. In summary we report a previously unrecognized crucial 
role for the RH domain of GRK5 and 6, and the subsequent identification of a lead peptide 
inhibitor of protein-protein interaction with potential for specific blockade of GPCR 
desensitization. 
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LAY SUMMARY 
STUDY OF THE ADRENERGIC RECEPTOR DESENSITIZATION 
Faiza Baameur, B.S., M.S. 
 
In the Fight or Flight response to danger, the autonomic nervous system releases a 
flood of adrenaline and noradrenaline (also termed epinephrine and norepinephrine) that 
triggers many important biological reactions. One key response is the relaxation of bronchial 
smooth muscles through binding of adrenaline to the beta 2 adrenergic receptor; this leads to 
an increase of air flow into the lungs. Drugs that mimic this action, termed agonists, are 
clinically very important in the treatment of asthma and other diseases. As with most 
biological processes the effect of the drugs is limited by the desensitization process that 
involves enzymes (protein kinases) which modify the receptor making it less responsive. 
Our studies are aimed at identifying key structural hotspots on the kinases that are involved 
in activation by the beta 2 adrenergic receptor, and based on that knowledge the 
development of specific inhibitors of desensitization that could prolong the action of 
clinically important drugs. In the present study we have found one of the hotspots 
responsible for adrenaline activation of the kinases and based on this discovery developed an 
inhibitor that blocks the process of desensitization. 
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CHAPTER 1 
INTRODUCTION   
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1.1 THE β2AR: STRUCTURE AND FUNCTION 
 
The adrenergic receptors are members of the G Protein-Coupled Receptors (GPCR) 
family, the largest superfamily of proteins encoded in the human genome. Structurally, the 
GPCRs consist of seven transmembrane α-helical domains connecting an extracellular N-
Terminus and an intracellular C-Terminus through three extracellular and three intracellular 
loops (Figure 1). They are divided into subclasses based on sequence homology and 
pharmacology. The adrenergic receptors (AR) are class A GPCRs (Rhodopsin-like 
receptors), the most extensively studied class (1). ARs are targets for endogenous 
catecholamines (epinephrine and norepinephrine) and for many medications, leading to 
either their activation or blockade. The ARs are widely distributed in the body, and the 
binding of an agonist generally causes a “fight or flight” response. There are nine adrenergic 
receptors which are divided into two subfamilies, the α1- and α2-receptors (three of each) 
and the β-receptors (βAR) of which there are three subtypes (β1, β2, and β3) (2). Our 
research group focuses on the understanding of the mechanisms of the β2AR activation and 
desensitization.  
The β2AR is expressed in many tissues and it plays a central role in relaying signals 
from the autonomic sympathetic nervous system to, most notably, the cardiovascular and 
pulmonary systems where β2AR activation causes an increase in heart contraction, and 
relaxation of lung tracheal smooth muscle (3). Numerous agonists of the β2AR such as 
albuterol, salmeterol and formoterol are used in the treatment of asthma and chronic 
obstructive pulmonary disease (COPD) causing vasodilation of tracheal smooth muscle. 
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βAR antagonists such as metoprolol and propranolol used in the treatment of hypertension, 
though mainly acting on β1ARs also inactivate the β2AR (3, 4).  
 
PM
Cytosol
Figure 1. Diagram of the β2AR. The figure shows the amino acid sequence of the receptor. 
The plasma membrane is represented in blue. GRK phosphorylation sites (S355, S356, 
T360, S364), PKA (and PKC) phosphorylation sites (S261, S262, S345, S346) are 
highlighted in black and red respectively. Yellow residues are tyrosine phosphorylation sites 
(5, 6). Palmitoylation site C341 is shown in green (7). Residues shown in green letters were 
previously reported as GRK phosphorylation sites (8), but subsequent studies showed these 
were not correct (9, 10). 
 
Agonist binding to and activation of the β2AR promotes its signaling and 
desensitization through complex cellular events (11). The mechanism of β2AR activation of 
adenylyl cyclase occurs through activation of the stimulatory G protein (Gs) which releases 
GDP and binds GTP upon agonist-activation of the receptor. Gs is a heterotrimeric protein 
comprised of the subunits (αβγ), which upon activation stimulates in a complex manner 
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various isoforms of adenylyl cyclase (AC). AC activation in turn generates cyclic adenosine 
monophosphate (cAMP) that activates Protein Kinase A (PKA), ion channels, and EPAC 
regulating many downstream pathways (12). Agonist activation of the β2AR leads 
essentially to two desensitization pathways known as the heterologous PKA-dependent 
pathway which is a G protein dependent pathway (13), and the homologous G Protein-
Coupled Receptor Kinase (GRK)-dependent, a G protein-independent pathway (14, 15). 
Figure 2 illustrates these pathways. However, other studies also involve the β2AR-induced 
activation of the Mitogen Activated Protein kinase (MAPK) (16) a G protein-independent 
pathway; as well as a tyrosine kinase Src-dependent pathway (17).  
 
Figure 2. Model of β2AR desensitization. Both heterologous (PKA-dependent) and 
homologous (GRK-dependent) pathways are represented. R: receptor; Arr: β-arrestin. 
P1PKA: p-S262; P4: p-S 355, 356, 364 and p-T 360. 
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1.2 β2AR REGULATION AND DESENSITIZATION 
 
1.2.1 The heterologous desensitization pathway 
 Original studies of the β2AR in wild type (WT) S49 lymphoma cells showed that 
β2AR agonist or PGE1 activation caused a two- to three-fold increase in the EC50 for 
epinephrine stimulation of AC, while no change was observed in cells lacking either PKA or 
AC (18). This process known as heterologous desensitization was attributed to elevated 
intracellular cAMP and subsequent activation of PKA. Our group found that the activated 
PKA phosphorylates the β2AR primarily at serine 262 in intracellular loop 3 (13, 19), 
although there is some indirect evidence for phosphorylation of residue S346 in the C-
terminus (20). Both are sites compatible with the consensus pattern for phosphorylation by 
PKA (RRxSR/K). In addition to regulation of the β2AR, PKA has been shown in many 
systems to activate phosphodiesterase (PDE4D subtype in our system). This action along 
with receptor phosphorylation, combine to generate a negative feedback on β2AR function 
(21, 22). 
 
1.2.2 The homologous desensitization pathway 
In an early study our group demonstrated that saturating levels of epinephrine 
stimulation of the β2AR caused desensitization of the receptor in S49 lymphoma cell that 
lacked AC, suggesting that neither Gs nor increased cAMP levels were required in this 
process (15, 18). This mode of desensitization is known as the homologous desensitization 
(23), as it depends on relatively high occupancy of the receptor by a strong agonist (EC50 = 
30-50 nM), and is closely correlated with the internalization of the receptor. Stimulation of 
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the receptor causes the rapid activation of GRK in a G protein-independent manner. GRK in 
turn phosphorylates at least three serine residues in the proximal C-terminus of the receptor, 
namely S355, S356, and S364. Identification of these three residues for GRK-mediated 
desensitization was shown through mutagenesis studies. Substitution of these residues with 
alanine, singly and in various combinations, in a receptor lacking the PKA consensus sites 
severely impaired desensitization (9). The S-(355, 356) site has been further characterized 
by the use of a phosphosite-specific antibody directed against pS-(355,356) (10). The EC50 
for epinephrine-induced phosphorylation of the GRK site was 200 nM following a 1 min 
treatment, or 30 nM with 10-30 min treatment (Tran 04). Mass spectrometric analyses 
further confirmed a stoichiometry of phosphorylation of the β2AR C-terminal fragment 
(residues 339-369) of 2 mol of phosphate / mol β2AR in the presence of saturating levels of 
agonist (10 µM isoproterenol (ISO)) and 1 mol of phosphate/ mol β2AR in the absence of 
agonist (24). These findings along with their finding of 1 mol of phosphate / mol β2AR in 
the third intracellular loop are consistent with our group’s previous characterization of S355, 
356, and 364 as the major GRK phosphorylation sites, and S262 as the major PKA 
phosphorylation site, although this group did not sequence the peptides in their mass 
spectrometry study. 
Notably, GRK phosphorylation of the β2AR causes little desensitization. Rather, the 
agonist-occupied and GRK-phosphorylated receptor recruits β-arrestin (arrestins 2 & 3), 
leading to the termination of the signal as it physically uncouples the receptor from Gs (25, 
26). Further, the β2AR-arrestin complex then interacts with clathrin-coated pits involving 
the adaptor protein AP-2 leading to receptor internalization or endocytosis (27). This process 
occurs with a rate of 0.22 / min (10). The EC50 for internalization is very similar to that for 
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GRK-mediated phosphorylation (~ 100 nM) (28). Dephosphorylation of the GRK-
phosphorylated receptor was proposed to occur only in endosomal vesicles following 
internalization (29). However, our group has demonstrated that dephosphorylation of both 
GRK and PKA sites in HEK293 cells can also occur at the plasma membrane (30), with a 
slow rate of ~ 0.04 / min. The specific phosphatase(s) involved remains an open question as 
phosphatase inhibitors are insufficiently specific enough to resolve this question, although 
both PP2A and PP1 blockade are possibilities (30, 31). 
The fate of the internalized receptor is either recycling (0.091 / min) (10) to the cell 
surface in a fully sensitized state (32), or downregulation where receptor is targeted to 
lysosomes for degradation (0.002 – 0.004 / min) (33, 34). Our group has also shown that the 
rapid phase of resensitization of ISO-stimulated AC activity was much faster than GRK site 
dephosphorylation, occurring with a rate of ~ 0.44 / min. We have proposed that dissociation 
of these two events is attributable to the rapid dissociation of β-arrestin upon agonist 
removal (25), and that the persistent GRK phosphorylation on its own causes little 
desensitization (30). Additionally, kinetic modeling done by Sharat Vayttaden in our group 
shows that surface dephosphorylation as well as recycling of phosphorylated receptor are 
necessary to account for the measured dephosphorylation and resensitization rates 
(submitted for publication). 
 
1.3 THE GRKs: STRUCTURE, FUNCTION, AND REGULATION 
 
The serine/threonine G protein-coupled receptor kinase family includes seven 
members, GRK1-7, classified into three subfamilies on the basis of their sequence 
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homology, the rhodopsin kinase subfamily (GRK1 and 7) in the visual system, the β 
Adrenergic Receptor Kinase (βARK) subfamily (GRK2, and 3), and the GRK4 subfamily 
(GRK4-6) (35-37). GRKs share common structural features. They all consist of a 
moderately conserved N-terminus RGS Homology (RH) domain (~ 185 amino acid 
residues), a highly conserved central kinase domain (~ 270 amino acid residues), and a 
poorly conserved C-terminal domain of variable length (100-230 residues) that includes a 
Plextrin Homology (PH) domain for only the βARK (GRK2 and 3) subfamily (38). The C-
terminus of the various GRKs is a key determinant for localization and/or translocation of 
the kinase to the membrane where their GPCR substrates are located (Figure 3). Among the 
GRKs only GRK2, 3, 5 and 6 are widely expressed in mammalian tissues; GRK1, 7 and 4 
tissue distribution is limited (37). 
 
Figure 3. Structure of GRKs.  
 
The PH domain of GRK2 and 3 has been shown to bind tightly to the Gβγ subunit 
which is presumably released in response to activation of the G protein by the stimulated 
GPCR, hence mediating GRK translocation to the plasma membrane (39). All other GRKs 
exhibit a constitutive association with the plasma membrane; the rhodopsin kinases contain 
a CAAX motif which undergoes an isoprenylation modification (40, 41), whereas splice 
variants of GRK4 and GRK6 are palmitoylated at cysteine residues which plays a role in 
anchoring them to the membrane (42-44). The non-palmitoylated variants may differ in their 
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regulation (45). GRK5 does not appear to undergo lipid modification, yet it is tightly bound 
to membrane phospholipids through a basic region (552-562) in its C-terminus (46, 47). All 
GRK4 subfamily members contain a phosphatidylinositol-4,5-bisphosphate (PIP2) binding 
site that also contributes to membrane binding and activation (48, 49), and a nuclear 
localization sequence at their N-terminus, which confers a potential nuclear function (50), as 
it has been shown recently that GRK5 phosphorylates histone deacetylase in rat myocytes 
(51). 
These kinases appear to play a role beyond the regulation of GPCRs; that is they are 
known to phosphorylate non-receptor substrates such as β-arrestin (52), tubulin (53), 
synuclein (54), and epithelial Na+ channel (55) to name a few although the physiological 
relevance is unknown. Furthermore, GRKs may modulate cellular functions in a 
phosphorylation-independent manner by interacting with a variety of proteins involved in 
signaling and trafficking; e.g., Gαq (56), caveolin (57), Gβγ, and PI3K (58); and may serve 
as scaffolds (59). Additionally, GRK isoforms undergo differential modifications which 
regulate their activity, such as phosphorylation by protein kinases PKA, PKC, and c-Src (58, 
60-62), autophosphorylation (46, 63, 64), and association with calcium-sensing proteins (65, 
66). These studies have been for the most part accomplished by the use of heterologous 
systems where rhodopsin phosphorylation has been assessed; however, there is a marked 
reduction in the apparent affinity of GRKs for rhodopsin relative to the rapid GRK 
phosphorylation of their cognate receptors in intact non-visual cells. In the light of these 
studies, GRK activity is not only regulated by GPCRs, but subcellular localization, 
expression levels in the different cells and tissues, alterations in intrinsic activity by protein 
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kinases and other proteins, and autophosphorylation also constitute important aspects of the 
mechanism of GRK regulation (67). 
Importantly, crystal structures of GRK1, 2, and 6 representatives of the three 
subfamilies in the inactive state have been resolved by the Tesmer group. GRK2 was first 
crystallized in complex with the βγ subunits of the G protein (68, 69), and later in complex 
with both Gβγ and the α subunit of Gq at two distinct sites of the RH domain (70), providing 
further support to earlier studies which reported the interaction of both GRK2 and 3 with G 
protein subunits (56, 71, 72). Subsequently, crystal structures of GRK6 complexed with 
AMPPNP as well as that of GRK1 in different ligand bound states were defined (73, 74). 
Although these structures revealed key elements in GRK regulation, the sites of GPCR 
interactions with the GRKs, and the transition to the active state conformation remain poorly 
defined. 
  
1.4 SPECIFICITY OF GRKs IN β2AR DESENSITIZATION 
 
Since the cloning of the first member of the GRK family (GRK1), structure, 
function, activation and regulation of these kinases have been the subject of numerous 
studies. However, little is known about which GRKs in different cell types are involved in 
regulating their substrate receptors (75). Though, GRK1-6 have all been shown to 
phosphorylate the β2AR (35, 36, 76-79) , GRK2 has been considered the dominant activity 
in β2AR desensitization (80), as it translocates to the plasma membrane through its binding 
to Gβγ (35, 80) and interference with Gβγ action impairs β2AR desensitization. Alone this 
aspect does not contribute directly to the question of the relative role of GRK2 in β2AR 
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desensitization relative to other GRKs. A number of other studies have attempted to identify 
the specific GRK(s) that mediate β2AR phosphorylation. These include knockdown of 
different GRKs in HEK293 and U2-OS cell lines (81), use of inhibitors (82, 83), 
overexpression systems (84), transgenic mice (85), and knockouts approaches (37, 80). 
These findings and related studies of several other GPCRs were the basis of the proposal 
that different GRKs may phosphorylate unique sets of sites on GPCRs. In spite of all these 
research efforts the identity of the predominant GRK involved in physiological regulation of 
β2AR remains under question, although the Lefkowitz group has implicated GRKs 2-6. This 
issue is compounded further by the expression level and localization of the GRKs in the 
different cell types and tissues.  
Recent work from our group demonstrated that GRK5 plays a major role in β2AR 
GRK site phosphorylation in HEK293 and COS7 cells. This was verified by a cell-free 
membrane assay, Bioluminescence Resonance Energy Transfer2 (BRET2) analyses, and 
overexpression of GRKs 2, 5, and 6 (86); and is discussed in detail in the next chapter as we 
explore domains of GRK5 and 6 that may be involved in β2AR activation of these kinases. 
   
1.5 EVIDENCE FOR GPCR-GRK INTERACTION 
 
In order to understand the mechanism underlying the activation of GRK by the 
agonist-activated β2AR, it is essential to investigate the molecular details of the interaction 
between these two proteins, concerning which domains of the GRK and the receptor are 
required for their interaction, and as noted above, at present little is known. An original 
study by Palczewski et al., showed that an enzymatically truncated rhodopsin (Rho) that 
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lacks the C-terminal phosphorylation sites (329G-Rho*) was able to stimulate GRK1 
phosphorylation of a peptide substrate indicating that the 329G-Rho could bind an allosteric 
site of GRK1 removed from the catalytic domain (87). Moreover, studies based on site-
directed mutagenesis and generation of deletion mutants of rhodopsin kinase and GRK2 
further demonstrated the existence of an allosteric binding site of GPCRs to GRKs in 
addition to the obvious catalytic binding site (88, 89). Other studies have been reported on 
identification of GRK(s) sites responsible for interaction with GPCRs, many of which 
involved the N- and C-termini.  
It was first shown that an antibody directed against residues (17-34) in the N-
terminus of rhodopsin kinase inhibited phosphorylation of Rho*, but not of a peptide 
substrate, suggesting the N-terminus is important in recognizing the active Rho (89). A 
GRK2 N-terminal fragment (residues 45-178) was shown to be sufficient to cause 
desensitization of the metabotropic glutamate receptor 1 (mGluR1) (90). Later this same 
group showed that a single residue, D527, localized to the C-terminus was essential for the 
GRK2-mGluR1 interaction (91). Moreover, mutations within the N-terminus of GRK5, 
namely L3Q-K113R and T10P as well as well as the deletion of the amino-terminal portion 
(residues 2-14), were shown to release the inhibition of the pheromone-activated growth in a 
yeast based bioassay and to significantly decrease both Rho* phosphorylation and 
phospholipid-activated GRK5 autophosphorylation (92). This was attributed to loss of 
GRK5 binding to the phospholipids. A C-terminal amphipathic helix was also shown to 
mediate membrane localization of GRK5 through hydrophobic residues, as alanine and 
glutamine substitutions of L550, L551, L554, and F555 failed to localize to the plasma 
membrane and reduced GRK5 autophosphorylation and phosphorylation of Rho* (93). 
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Another study involved a proline-rich motif within the C-terminus of GRKs 1, 2, and 5; this 
was shown to mediate kinase association with the light-activated rhodopsin (71, 72). Very 
recently, based on the crystal structure of GRK1 that includes the previously undetermined 
structures of the N- and C-termini, Singh et al., suggested that the site composite of the N-
terminus, the C-terminal extension of the kinase domain and the small lobe of the kinase 
domain proximal to the hinge region, serves as the allosteric receptor docking site (74). 
Despite all these efforts, resolution of the allosteric interaction site on GRKs has not been 
forthcoming. These findings are summarized in Table 1.  
Table 1. Summary of effects of GRKs 1, 2, and 5 mutations 
GRK1 GRK2 GRK5 Results ET rank Ref 
GRK1 
N-Ter (17-34)   Antibody inhibits Rho* 
phos. 
 (89) 
S488A-T489A x* S484,T485 Autophos. (-)#; Rho 
phos. (+)# 
x (94) 
K491A K494 K487 Peptide substrate phos. 
(-) 
x (94) 
S21 K19 G18 PKA site; Rho phos. (-) x (62) 
F3A, L6A, V9A, 
V10A, S13A, F15A 
M1, L4, V7, L8, 
V11, Y13 
x, L3, I6, V7, 
T10, L12 
Recoverin binding (-) 
No effect on activity 
x (95, 
96) 
N-Ter (5-30), C-Ter 
extension of KD 
  Suggested receptor 
docking site 
 (74) 
S5, T8 D3, A6 E2, N5 Autophos. No effect on 
Rho phos. 
x (74) 
Helix 9    Dimer in crystal 
structure 
 (74) 
R191A/K R195A R190A Activity (-); 
Rho phos (-) 
1 (97) 
Δ N-Ter (1-19)   Activity (-)  (97) 
GRK2 
Q107, x, Q117, 
A123, L125 
R106A, F109I, 
D110A, E116A, 
L118A  
L102, x, x, K113, 
P115 
Gαq binding (-) 11.23, x, 
x, 9.85, 
8.18 
(72, 
98, 
99) 
R31 S29 K28 PKC site; Rho phos. (+) 4.95 (100
) 
x S685 x PKA site, β2AR phos. 
(+) 
x (101
) 
 N-Ter (45-178)  mGluR1 binding (+);  
signaling (-) 
 (90) 
G529 D527A K522 mGluR1 binding (-) x (91) 
x K567A, W576A, 
R578E, R579A 
N562 T571 F573 
N574 
β2AR phos. (-) x (102
) 
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x K663-, K665-, 
K667-, R669-E/Q 
x Gβγ response (-) x (69, 
102) 
 N-Ter (1-185) and 
(1-53) 
 Gβγ binding (+)  (69, 
103) 
F15, W89, Y95 Y13, Y86, Y92 L12, L84, Y90 c-Src sites; Gαq binding 
(+) 
x, 3.59, 
3.8 
(104
) 
K46, S49, x, E518 V42E, Y46A, 
P638D, E520A 
Q41, L45, x, E514 Rho phos. (-); 
expression (-) 
7.79, 
1.66, 
2.35 
(68) 
V478 V477D V472 Activity (-); 
Rho, β2AR phos. (-) 
2.9 (105
) 
S5, L6, N12 D3K, L4A, D10A E2, L3, N9 Activity (-); 
Rho, β2AR phos. (-) 
x (106
) 
GRK5 
S488, T489 x S484A-T485A Autophos. (-); Rho 
phos. (-) 
x (46, 
79) 
S27, P29, R31, K33, 
K34, Q28 
T23, A25, R27, 
S29, K30, P24 
K(22-24-26-28-
29)A + R23A  
PIP2 binding (-); actin 
binding (-) 
x, x, x, 
4.95, 
4.19, x 
(49, 
107) 
  N-Ter (20-39) Calmodulin binding (+)  (61) 
L6, Q117, S13 L4, E117, V11 L3Q-K113R, 
T10P 
Rho phos. (-); PIP2 
binding (-) 
x, 9.85, x (92) 
G558, M559, V562 
S563 
L555, G556, C559, 
I560 
L550A-L551A-
L554A-F555A 
(4A) or (AALF) 
or (LLAA) 
PM localization (-); 
Rho phos. (-); 
autophos. (-) 
x (93) 
P(467-468-471)A P(467-468-469-
472)A 
P(463-464-467)A Rho phos. (-) 1.7, 1.7, 
1.7 
(108
) 
R394, G395, K397, 
E399, N400 
H393, K394, K396, 
K398, H399 
R388A-K389A-
K391A-K393A-
R394A 
Nuclear exclusion 4.55, 
2.24, 
1.69, 
4.09, 4 
(50) 
K46 V42 Q41L 
polymorphism 
β2AR desensitization 
(+) 
 (109
) 
Residues corresponding to those examined (black) in either one of the GRKs are shown in 
blue 
Ranks for important residues are given in red 
* Unavailable ranks or residues in the corresponding GRKs are represented by “x” 
# (-) and (+): negative and positive effects respectively  
Phos. : phosphorylation; KD: Kinase Domain; Ter: Terminus 
 
Another intriguing aspect of GRK structure, function, and regulation derives from 
increasing evidence that expression levels and mutations of the GRK family may lead to 
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disease states, mainly in the cardiovascular system where GRK2 and 5 are mostly expressed 
(110-115). Elevated GRK protein expression and or mRNA level or deficiency of specific 
GRKs in both animal models and humans, were associated with many diseases (Heart 
failure, myocardial ischemia, hypertension, rheumatoid arthritis, and hypothyroidism to cite 
a few) as reviewed by Metaye et al. (85). However, recently a GRK5 polymorphism (Q41L) 
that appears to have increased activity resulting in greater desensitization of the β2AR was 
found to protect against congestive heart failure through blockade of the βAR signaling 
(109). We have also found a mutation in the RH domain that increases GRK5 activity and 
that we will discuss in chapter 2. 
 
1.6 PEPTIDE MODULATORS OF GRK ACTIVITY 
 
 Disruption of protein-protein interaction is one of the most common approaches used 
in analyzing protein contact sites. This provides a unique perspective in understanding 
mechanisms regulating protein-protein interaction and ultimately developing tools to inhibit 
that interaction. Various kinds of inhibitors have been used to study GPCR regulation of 
GRK including pharmacological agents e.g. H7; or poly-anions and -cations e.g. dextran 
sulfate, heparin, polylysine (116). However these compounds are more likely to inhibit the 
catalytic activity rather than blocking the site of interaction with the GPCR, and further, they 
lack specificity. One way to circumvent this is through development of peptide disruptors 
mimicking interaction domains of GPCR-GRK. This is exemplified by the original work of 
Benovic et al., in which they synthesized peptides mimicking each of the intra- and extra-
cellular loops as well as two portions of the C-terminus of the β2AR and were able to show 
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in a reconstitution system that the intracellular loop 1 (il-1) (residues 56-74), and C-terminal 
portion (residues 219-243) peptidomimetics inhibited GRK2 phosphorylation of the receptor 
with IC50s of 40 and 76 µM respectively (117), suggesting that multiple β2AR sites may be 
involved in its interaction with GRK as modeled in Figure 4. Subsequently, modification of 
the il-1 peptide sequence by either truncations or addition of charged residues led to a more 
potent peptide that inhibited GRK2, 3, and 5 activities with IC50s of 0.6, 2.6, and 1.6 µM 
respectively (83). This peptide was further shown by Xin et al. to inhibit the desensitization 
of the endogenous β2AR in HEK293 cells (22). Moreover, inhibitors of the Gβγ interactions 
with various effectors were developed based on the identification of the βγ “hotspot”, and 
they may serve as potential therapeutic agents (118). Importantly, recent complementary 
studies, one involving the isolation of a stable Rho*- Gt (transducin) complex (119), and the 
other the resolution of the crystal structure of the Gαt C-terminus bound to opsin* (120), 
provided molecular insights on how GPCRs interact with their partner proteins (G protein, 
GRK, Arrestin). These studies provide evidence that peptide mimetics of interaction sites 
can modulate protein function/regulation. Similarly, Pao et al., showed that the amino-
terminal peptide of GRK2 (residues 1-14) inhibited non-competitively β2AR* and Rho* 
phosphorylation by GRK2 (106). Collectively, these pioneering studies lay groundwork for 
development of specific and effective inhibitors of GRKs. 
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 Figure 4. Venn diagram representing hypothetical contact sites between β2AR and G 
protein, GRK, and β-arrestin. Interaction of these proteins with the receptor may involve 
multiple partially overlapping domains on each protein (left), e.g. the C-terminus, il-1, il-2, 
il-3 and helix 8 of the β2AR. Another possibility is that the interaction domain involves one 
relatively discrete site on each protein (right). 
 
Thus the goal of our study is to determine the structure and function of 
important domains in the GRKs in order to approach an understanding of the 
mechanism and specificity of the GPCR-GRK interactions, and eventually develop 
specific and effective inhibitors of GRKs. 
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CHAPTER 2 
FUNCTIONAL STUDIES OF THE GRK RH DOMAIN 
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2.1 INTRODUCTION 
  
At present we know very little about how GPCRs activate GRKs. Since this 
activation requires the activated state of GPCRs it is presumed that the mechanism will be 
analogous to GPCR binding to and activation of G proteins, and the binding of arrestins to 
the GRK-phosphorylated agonist-occupied receptors. From this analogy it seems likely that 
the surface of interaction will involve multiple interaction domains from the perspective of 
both the receptor (e.g., possible involvement of all the intracellular loops and helix 8), and 
from the matching sites on GRKs. While there have been many studies of possible 
interaction sites, at present little is known other than that it involves an allosteric interaction 
that may require contributions from both the RH and the kinase domains as well as sites 
required for docking to the membrane. 
 To approach this outstanding problem we first conducted an Evolutionary Trace of 
the GRK family in collaboration with Dr. Olivier Lichtarge’s group at Baylor College of 
Medicine. As will be shown below this led to the identification of clusters in both the RH 
and kinase domain that indicated they could play important roles in GRK activation. From 
the following considerations we focused our studies on clusters in the RH domain: 1) that 
they had not previously been indicated as important or studied in detail; 2) that the allosteric 
interaction might involve sites other than those centered on the small and large lobes of the 
kinase domain; and 3) that mutations in and around the catalytic domain might simply 
disrupt this domain rather than blocking the putative allosteric site. 
 Following the ET study we selected highly ranked regions of the RH domain for 
focused mutagenesis and functional assays using: 1) intact cell assay of basal (constitutive) 
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β2AR phosphorylation in HEK293 cells following transfection of GRK5 and GRK6, and 2) 
in vitro light-activated rhodopsin phosphorylation by 21K membrane preparations of GRKs 
from transiently transfected HEK293 cells. Our focus on the β2AR and GRKs 5 & 6 derived 
from both our previous work and that of others demonstrating the importance of these GRKs 
in β2AR phosphorylation as reviewed in Chapter 1. 
 
2.2 MATERIALS AND METHODS 
 
Materials: Human Embryonic Kidney (HEK293) cells were purchased from the American 
Type Culture Collection (Manassas, VA). Cell culture reagents are from Mediatech 
(Herdon, VA). Lipofectamine 2000 and TOP 10 competent cells are from Invitrogen 
(Carlsbad, CA). Peptide N-glycosidase F (PNGaseF) was from New England Biolabs 
(Beverly, MA). Polyclonal primary antibodies to pS-(355,356) C-Tail of the β2AR, and to 
GRK2, GRK5, and GRK6 are from Santa Cruz Biotechnology (Santa Cruz, CA). N-terminal 
6 His-tagged, recombinant, full length, human GRK5 was purchased from Millipore 
(Dundee, UK). The HRP-conjugated secondary antibody was from BioRad. Enhanced 
chemiluminescence SuperSignal reagent was purchased from Thermo Scientific (Rockford, 
IL), and hyperfilm was from Amersham Biosciences (Piscataway, NJ). QuickChange Site-
Directed Mutagenesis Kit and XL1-Blue supercompetent cells were from Stratagene (La 
Jolla, CA). SP-Sepharose Fast Flow was purchased from GE Healthcare (Piscataway, NJ). 
  
2.2.1 Cell culture 
HEK 293 cells stably overexpressing Flag-tagged wild type (WT) β2AR (WT-β2AR) 
at 2-4 pmol/mg membrane were grown in 5 % CO2 at 37 °C in Dulbecco’s Modified Eagle’s 
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Medium (DMEM) containing 10% fetal bovine serum, 100 units/ml penicillin, 100 μg/ml 
streptomycin, and 200 μg/ml G418. When seeding cells for experiments dishes were coated 
with poly-L-lysine to aid attachment. 
 
2.2.2 Evolutionary trace analysis 
Using ET analysis, protein-protein interaction sites can be predicted and be further 
characterized by experimental techniques. The trace is run by loading the single chain 
sequence of the protein of interest in the PDB format (121). Ranks and percent coverage are 
assigned to each alignment position correlating variance and evolutionary divergence. 
Residues corresponding to the top 30th percentile are evolutionarily important and 
deterministic of protein function. They typically form statistically significant clusters when 
mapped onto the representative 3-D protein structure (122, 123). As an extension to this 
technique, the Lichtarge group developed the Difference ET methodology that identifies ET 
residues within a subfamily of proteins of a phylogenetic tree as compared with the globally 
important residues within the encompassing superfamily (124). 
Difference ET analyses were run by Drs. Yao and Morgan from the Lichtarge group 
to identify specific amino acids functionally determinants in the RH and kinase domains of 
the GRK subfamily. Since no crystal structure of GRK5 has been resolved yet, the crystal 
structure of GRK6 (PDB ID: 2ACX (73)) was used for visualization of ET residues on a 3D 
structure (GRK6 and GRK5 are  > 70% homologous in their amino acid sequence (125)). To 
rank the important ET residues within the GRK subfamily as compared with the large 
Serine/Threonine kinases superfamily, Difference ET analysis was performed on the RH and 
kinase domains separately. For the RH domain, 56 aligned sequences of GRKs (GRK1-7) 
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from different species were included as part of a global alignment of 270 sequences of the 
RGS proteins superfamily. Likewise, for the kinase domain, 50 aligned sequences of GRKs 
were included as part of a global alignment of 463 sequences of the Serine/Threonine 
kinases superfamily. The superfamily ET residues were then subtracted from those of the 
subfamily to isolate GRK specific important sites. Residues in the 30th percentile rank 
produced evolutionarily important clusters. Ranks and percent coverage are given in 
Appendix 1.  
 
2.2.3 Mutagenesis of top ranked residues 
The WT hGRK5 (NM_005308), hGRK6 (NM_001004106), and hGRK2 
(NM_001619) cDNA plasmids were cloned into pcDNA3.1 +. The cDNA plasmid of 
membrane tethered GRK2-PP was also cloned into pcDNA3.1 +. It was constructed by 
adding a cDNA sequence to its C-terminus that encodes a GFP2 tag and an extra 17 amino 
acids k-ras sequence (KDGKKKKKKSKTKCVIM). This peptide contains a polybasic 
region and a prenylation site to ensure its plasma membrane localization. These plasmids 
were all gifts from Dr. Rasmus Jorgensen (7TM Pharma, and NovoNordisk, Denmark). All 
clones were verified by DNA sequencing.  
Another hGRK5 cDNA plasmid cloned in pcDNA3.1 + used in our first mutagenesis 
studies was a gift from Dr. Jeffrey Benovic (Thomas Jefferson University, PA). When 
sequenced this GRK revealed three non-synonymous substitutions in the coding region as 
compared with the WT GRK5 (NM_005308); namely, sequences at positions 310 (G to A), 
911 (A to G), and 1313 (G to A). These three base changes alter the amino acid sequence 
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such that E104→K, R304→H, and G439→E. This GRK5 mutant will be referred to as 
KHE-GRK5. 
For WT & KHE-GRK5 and GRK6 plasmids, single and double alanine substitutions 
of ET residues were generated as listed in Table 2 and shown in Appendix 2, using the 
QuickChange Site directed mutagenesis kit. Mutagenic oligonucleotide primers were 
designed to convert the above residues to alanine as listed in Appendix 3. The template 
pcDNA 3.1 + - GRK5/6 (10 ng) and the two complementary oligonucleotide primers 
containing the desired mutation (125 ng each) were extended by Pfu Turbo DNA 
polymerase using the Px2 Thermal Cycler. The plasmid was then treated with Dpn I 
endonuclease to select for the mutated plasmid and then was transformed into XL1-Blue 
supercompetent or One Shot TOP10 competent cells. The transformation reaction was then 
plated onto LB-agar plates containing ampicillin. Plasmids were purified using the QIAprep 
Spin Miniprep Kit and direct DNA sequencing of the entire GRK5 coding region was 
performed on all plasmids to confirm the predicted sequence.  
Table 2. List of mutations   
mutations # location mutations # location 
GRK5 KHE-GRK5 
F36,  P37,  H38 loop α0-α1 P61,  L66,  R68 α3 
C42 α1 D85 α4 
P61,  I62,  L66,  R68,  Q69 α3 F166 α9 
F166,  R169,  Q172,  W173,  L176 α9 P510,  E514,  E517,  T518 α10 
E514 α10   
P61-Q69 α3 GRK6 
F166-Q69,  F166-P61,  F166-L66 α3-α9 L66,  R69 α3 
L66-H38,  L66-P37 α3-loop Y166,  L176 α9 
F166-E514 α9-α10 L66-R69 α3 
L66-E514 α3-α10  Y166-L66,  L66-Q172 α3-α9 
F166-Q172,  F166-W173,  Q172-L176 α9 Y166-Q172,  Y166-L176,  Q172-W173 α9 
E104K,  R304H,  G439E α5, KD, KD* # Residues mutated to Ala except where mentioned 
S484-T485 KD * KD: Kinase domain 
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2.2.4 Intact-cell phosphorylation of the β2AR by WT or mutant GRK5/6  
WT-β2AR cells (2.5 × 105) were grown in 35 mm plates to reach 70-80 % 
confluence after 24 hours. Using Lipofectamine 2000 transfection reagent, cells were 
transiently transfected with 150 ng of WT or mutant GRK5 or 6 and 1.35 μg of empty vector 
(pcDNA3.1+) cDNA plasmids (1.5 µg total cDNA / plate), with a DNA (µg) to 
Lipofectamine 2000 (µl) ratio of 1:3 (1.5 µg: 4.5 µl). Controls were transfected with empty 
vector only. After 48 hours, cells were treated either with the β2AR agonist isoproterenol 
(ISO) (100 nM), dissolved in the carrier, 0.1 mM ascorbate / 1 mM thiourea pH 7 (AT), or 
AT alone for 2 min at 37 °C. The medium was removed and cells washed twice with 1 ml of 
ice-cold phosphate-buffered saline (PBS). To solubilize the β2AR, the contents of each well 
were scraped into 500 μl of ice-cold solubilization buffer (20 mM Hepes, pH 7.4, 150 mM 
NaCl, 0.9% dodecyl-β-maltoside, 20 mM Na4PPi, 10 mM NaF, 20 μM Na3VO4, 10 μg/ml 
benzamidine, 10 μg/ml leupetin and 100 ng/ml okadaic acid). The samples were rocked for 
30 min and centrifuged at 21,000×g for 15 min at 4 °C to remove cell debris. The supernates 
were treated with 150 U PNGaseF for 2 hrs at 37 °C to allow deglycosylation of the 
receptor, and then heated to 65 °C for 15 min in SDS-sample buffer (2% SDS, 10% glycerol, 
100 mM Tris, pH 6.8, bromophenol blue, and 1mM dithioreitol (DTT)) (10). Samples were 
resolved on 12% SDS-PAGE, transferred to nitrocellulose membrane and immunoblotted 
first with anti-pS-355,356 antibody, then stripped and reprobed with anti-C-Tail antibody, 
and stripped again and reprobed with the anti-GRK5/6 antibodies. Western blots were 
visualized on film using SuperSignal, and band densities quantified using the Syngene 
software. Results were normalized first to the β2AR levels (anti-C-Tail) then to GRK5/6 
levels (anti-GRK5/6). 
24 
 
2.2.5 Preparation of GRK5/6 from 21K membrane fractions  
WT-β2AR cells were grown to ~ 60-80% confluence in 100 mm dishes. Cells were 
transfected with 8-10 μg of cDNA plasmid (vector, WT or mutant GRK as described above). 
After 48 hours cells were washed twice with ice-cold PBS and scraped into 1 ml of ice-cold 
lysis buffer (20 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1mM phenylmethylsulfonyl fluoride 
(PMSF), 20 μg/ml leupeptin, and 3 mM benzamidine), followed by homogenization with 7 
strokes of a Dounce homogenizer. Lysates were centrifuged at 600 × g for 5 min at 4 °C to 
remove all intact cells and nuclei. The supernate was centrifuged at 21,000 × g for 10 min at 
4 °C. Pellets were resuspended and washed twice with 1ml of lysis buffer, spun at 21,000 × 
g for 10 min at 4 °C to make 21K membrane fractions, then suspended in 1 ml of lysis 
buffer supplemented with 50 mM NaCl, 0.02 % TritonX-100, 1 mM DTT (86). Samples 
were frozen at -80 °C and either used directly after dilution, or partially purified on SP-
sepharose columns as described below.  
 
2.2.6 Purification of GRK5 on SP-sepharose  
Cell lysates were diluted 10 times in lysis buffer supplemented with 50 mM NaCl, 
0.02 % TritonX-100, 1 mM DTT, and applied to SP-sepharose column. The resin (250 μl) 
was washed six times with 2 ml of lysis buffer before eluting GRK5 with 20 mM Tris-HCl, 
1 mM EDTA, 450 mM NaCl, and 0.02% Triton X-100. The partially purified GRK5 was 
then diluted to a final salt concentration of 50 mM and assayed for rhodopsin 
phosphorylation (all steps at 4 °C). Purification of GRKs was assessed by westerns and the 
levels quantitated by reference to standard curves generated with purified GST-GRKs (10-
200 ng) or 6His-GRK5 obtained from Millipore. The GST-GRK fusion proteins were 
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generated by cloning the full length GRK cDNA plasmid into the pGEX-4T-1-GST vector at 
the 3’ end with BamH I and EcoR I restrictions sites. Plasmids were transformed in E. coli, 
and grown to produce fusion proteins. Bacterial lysates were purified by affinity 
chromatography on glutathione-sepharose resin as described in the Amersham Biosciences 
GST Gene Fusion System handbook (86). No GRK other than GRK5 was detectable in this 
fraction.  
 
2.2.7 In-vitro phosphorylation of light-activated rhodopsin by WT or mutant GRK5/6 
Urea-stripped Rod Outer Segments (ROS) were a generous gift from Dr. Kevin 
Ridge (The University of Texas Health Science Center in Houston, TX) and prepared as 
described by Wilden and Kuhn (126). WT and mutant GRK, solubilized as described above 
from WT-β2AR 21K membrane fractions or following purification with SP-sepharose 
chromatography, were diluted in lysis buffer (5-10 nM of GRK5 and GRK6) and incubated 
with 4 µM of rhodopsin in 20 mM Tris-HCl, pH 7.5, 1 mM EDTA, 10 mM MgCl2, and 100 
μM [γ32P]ATP at 30°C in a final volume of 32 μl (61). Rhodopsin was activated by 
illumination (475 nm) for 30 sec (127). Reactions were stopped after 10 min by addition of 
4X SDS-sample buffer (8% SDS, 60% glycerol, 0.4 M Tris-HCl, pH 6.8, bromophenol blue, 
and 0.4 M DTT). Samples were then resolved on 12% SDS-PAGE, transferred to 
nitrocellulose membrane, and 32P-labeled proteins were visualized by autoradiograms. Of 
note, samples were not heated after adding the SDS buffer to prevent rhodopsin precipitation 
in the stacking gel. With these levels of GRK5 or 6, rhodopsin phosphorylation was linear 
for 0 to 30 min. 32P-Rhodopsin bands were quantified by densitometry directly from 
autoradiograms, by using a Storm Molecular Dynamics Phosphorimager (GE Healthcare), 
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and by direct counting of excised bands; comparable results were obtained from these 
measurements.  
 
2.3 RESULTS 
 
2.3.1 Evolutionary Trace Analyses  
As discussed, functionally important residues in proteins can be identified based on 
specific evolutionary patterns using the ET method. Highly ranked residues for the GRK 
subfamily were generated by running two separate traces for both the RH (Figure 5) and the 
kinase domains (Figure 6). Analysis of the RGS proteins superfamily included the alignment 
of 270 protein sequences and the Ser/Thr kinase superfamily 463 sequences (Figures 5C and 
6C respectively) (Appendix 1-Tables A and C). Typically the top 30 % ranked residues form 
clusters that are thought to be key determinants of protein function. Additionally, a different 
set of rank scores for each residue was generated for only the GRK subfamily, this included 
56 or 50 sequences for the RH and the kinase domains respectively (Appendix 1-Tables B 
and D). Difference ET was then applied to isolate GRK-specific determinants from global 
determinants. Our study focuses on both GRK5 and 6, and since these two kinases are more 
than 70 % homologous in their amino acid sequence, and show near identical homology in 
the RH domain (125), ET results were mapped onto the GRK6 crystal structure (73) since 
no crystal structure has been yet resolved for GRK5. 
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 Figure 5. ET of the RH domain. Evolutionary trace results shows strong clustering of the 
highly ranked residues mapped onto GRK6 crystal structure (73). A. The phylogenetic tree 
of 270 analyzed sequences consisting of the RGS proteins superfamily including 56 GRK 
proteins with GRK1-7 from different species represented. B-E. ET results showing the top 
30% ranked residues in the RH domain of GRK6 with helix 11 and the kinase domain 
removed. B. Results of the GRK subfamily alone with a large cluster in terminal subdomain. 
C. Results of the superfamily showing global conservation in the bundle subdomain. D. The 
Difference ET results for the RH domain. E. Close up of conserved residues clustering in 
helices 3, 9, and 10. Red residues are subfamily specific while pink residues are conserved 
in both the GRK/RGS superfamily and GRK subfamily. Figure generated by Dan Morgan. 
 
ET analysis for the RGS proteins superfamily revealed a cluster of important 
residues centering on helices 4, 5, and 7 (Figure 5C).  A number of these residues in GRK2 
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helix 5 are known to form a binding interface with the Gαq subunit of the G protein both 
from mutagenesis and the crystal structure (R106, D110, L118, and Q133 (α6)) (98, 99). 
Similar analysis for the GRK subfamily revealed a distinct cluster of important residues 
(Figure 5B). Difference trace analysis uncovered a conserved cluster including helices 0, 1, 
3, 9, 10 and 11 (Figure 5D-E), presumably domains functionally important in the GRK 
subfamily. Residues within helices 0, 1 have been shown to be involved in membrane and 
PIP2 binding (48, 49). Likewise, Difference ET analyses for the kinase domain of the AGC 
kinase superfamily and the GRK subfamily were performed as represented in Figure 6. 
 
Figure 6. ET of the Kinase domain. A. The phylogenetic tree of 463 analyzed sequences 
of the AGC kinases superfamily including 50 GRK proteins (GRK1-7). B-D. ET results 
mapping the top 30% ranked residues onto the kinase domain of GRK6. B. Results of the 
GRK subfamily alone. C. Results of the kinase superfamily. D. The Difference trace results 
for the kinase domain. Yellow residues are subfamily specific while orange residues are 
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conserved in both the superfamily and subfamily; the green molecule represents AMPPNP. 
Figure generated by Dan Morgan. 
 
Trace analyses for both the RH and the kinase domains were combined for better 
visualization using the GRK6 structure (73) as shown in Figure 7. The domains unique to 
the GRK subfamily for the RH domain are colored in red and the kinase domain in yellow, 
and those residues shared by the GRK subfamily with the superfamilies are colored in pink 
and orange respectively. To test the potential importance of the conserved cluster in the RH 
domain, residues within helices 0, 3, 9, and 10, were targeted for mutagenesis and analyzed 
for functional effects. Of note, part of this site is buried under the C-terminus (helix 11), 
however, we reasoned that this site was still close enough to the surface to be accessible to 
GPCRs, and that the C-terminal tail as well as the N-terminus might possibly undergo 
conformational rearrangements that may expose it further. 
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 Figure 7. ET analysis mapped onto GRK6. GRK6 x-ray structure PDB code 2ACX (73) is 
shown in cartoon using PyMol Molecular Graphics System. The structure shows the 
Difference ET analysis of the RH domain (white and red), and the kinase domain (brown 
and yellow). Red and yellow colored residues represent the evolutionarily important 
residues unique to GRK subfamily. 
 
ET revealed other interesting features such as a clustering of lysine residues on an 
exposed surface proximal to the conserved cluster in the RH domain, which likely 
contributes to membrane binding (Figure 8). Of interest recent mutagenesis studies showed 
the importance of kinase domain residues (R191 in GRK1, and V477 in GRK2) in GPCR 
phosphorylation (105, 128), consistent with our ET analysis. However, for reasons discussed 
in 2.1, we did not further examine these residues for functional effects, but rather focused 
the present studies on the RH domain. 
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 Figure 8. Surface representation of ET residues mapped onto GRK6. Helices 3, 9 and 
10 are circled in red. On the right: a flat surface cluster shows basic residues identified by 
difference ET: K28, K29, R190, K210, K219, K220, R221, K223, and K256 (putative 
plasma membrane binding site). 
 
2.3.2 Mutagenesis of top-ranked residues in GRK RH domain  
To test whether the top-ranked residues in the RH domain are involved in activation 
of GRKs by GPCRs, mutations of over 30 key trace residues in the RH terminal subdomain 
were generated by both single and double alanine substitutions to avoid introducing any 
charged amino acids. Alanine mutations of these residues are allowed since variability at 
these positions does not include alanine, or rarely in a distant branch. Following the site-
directed mutagenesis, constitutive phosphorylation of the β2AR was used to screen for WT 
and mutant GRKs activity (10, 86). Following screening we employed in-vitro GRK 
phosphorylation of light-activated rhodopsin using urea washed ROS. 
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2.3.3 Constitutive phosphorylation of the β2AR 
 As already mentioned, our group had previously shown the important role GRK5 
plays in phosphorylating the β2AR GRK site (S355,S356) in intact cell and cell-free assays 
using both HEK 293 and COS7 cells (10, 30). Transient overexpression of either GRK5 or 6 
causes a strong constitutive phosphorylation of S-(355,356) of the β2AR in WT-β2AR cells, 
unlike GRK2 unless membrane tethered (10, 86, 129) as shown below in Figure 9. We feel 
that this constitutive phosphorylation of the β2AR likely reflects GRK phosphorylation of 
the R* or activated conformation of the receptor. This is based on our earlier studies and that 
of the Lefkowitz group that demonstrated increasing levels of basal AC activity correlated 
strongly with the level of transfected β2AR (130, 131). Thus given the 30-50 fold transient 
overexpression of GRK we observe in cells coupled with the high, stable expression of the 
β2AR it seems likely that the constitutive phosphorylation we observe is in fact a reasonable 
facsimile of agonist-activated β2AR phosphorylation. This is no doubt aided by the slow 
rate of dephosphorylation of the β2AR we have documented in these HEK293 cells (30). 
Irrespective of the validity of this argument, this approach allows us to assess GRK mutant 
activity in an intact cell setting, and it correlates well with our in vitro rhodopsin assay 
discussed below. 
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 Figure 9. β2AR constitutive phosphorylation by overexpression of GRKs. WT-β2AR 
cells were transiently transfected with either pcDNA 3.1+ (Control), GRK5, GRK2, GRK6, 
or GRK2-PP. After 48 hours, cells were treated with 100 nM ISO (filled bars) or the carrier 
AT (open bars) for 2 min, solubilized and processed for western blotting (Methods). The 
data were normalized to the total receptor levels (α-C-Tail) and are means ± SEM of three 
experiments. Representative western blots are shown next to the graph. 
 
To optimize the constitutive assay, GRK was transiently expressed over a range of 
cDNA plasmid levels in WT-β2AR cells. The level of 150 ng / 35 mm well was found to be 
optimal to achieve half the β2AR phosphorylation relative to 100 nM isoproterenol (ISO) 
activation (Figure 9). Measurement of receptor phosphorylation was assessed by western 
blotting with the anti pS-(355,356), followed by normalization to the receptor level with the 
anti C-tail antibody, and to the level of GRK expressed with the anti-GRK5 or -GRK6. 
 
2.3.3.1 Effects of mutant KHE-GRK5 
 As described in methods, the mutagenesis were begun using the KHE-GRK5 prior to 
our belated discovery that it was altered relative to the consensus hWT GRK5 (G104K, 
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R304H, and G439E) (Figure 10C).  Fortunately the activity of KHE-GRK5 is identical to 
that of the WT GRK5, and as it turned out, observations we made on this altered GRK5 have 
been of interest. The reason for this is that our first screen of a series of mutants of the RH 
domain revealed four residues in which substitution to an alanine caused a significant 
reduction in β2AR constitutive phosphorylation as compared to KHE-GRK5 (72 – 95 % 
inhibition); namely mutants P61A, L66A, F166A, and E514A (see Table 2 above 
summarizing these single alanine substitution mutations). Based on the X-ray structure it 
appears that the side chains of the four residues mutated are facing in different directions 
(Figure 10C). Importantly, the mutants’ expression levels were not significantly altered. 
Further discussion of these mutations of GRK5 will follow in the next section. 
   
Figure 10. Effect of KHE-GRK5 mutations on constitutive β2AR GRK site 
phosphorylation. A. WT-β2AR cells were transiently transfected with either pcDNA3.1+ 
(Control) or mutant KHE-GRK5. After 48 hours, cells were solubilized; lysates were run on 
SDS-PAGE, probed with anti-pS-355,356, then stripped and reprobed with anti-C-Tail, and 
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with anti-GRK5. The data were normalized to the total receptor levels and GRK5 levels. 
Several point mutations showed significant decrease in GRK site phosphorylation (*** p < 
0.001 by One-way ANOVA). The data are means ± SEM of at least five experiments. 
Representative Western blots of the constitutive phosphorylation of S-355,356, receptor and 
GRK5 levels are shown below the graph. B. Relative positions of residues 104, 304, and 439 
are shown in blue in the GRK6 crystal structure cartoon. C. Cartoon representation of 
helices 3, 9, and 10 showing side chains of ET residues (red) mapped onto GRK6 using 
PyMol Molecular Graphics system. 
 
2.3.3.2 Effects of WT and mutant GRK5  
After realizing the “extra” mutations in KHE-GRK5, we quickly performed similar 
point mutations in the WT GRK5. Surprisingly, none of these single mutations altered 
constitutive GRK phosphorylation of the β2AR as compared to the WT. To sort out this 
interesting observation, E104K, R304H, and G439E mutations were introduced into WT 
GRK5 either individually or as a pair along with any of the four mutants P61A, L66A, 
F166A, and E514A. We found that both R304H and G439E were required to reproduce the 
same effect seen with the KHE-GRK5 point mutants. Neither E104K-R304H nor E104K-
G439E mutants had a significant effect when combined with any single defective mutant. Of 
importance, neither one of these three residues is evolutionarily important, but they are 
positioned in the bundle – large lobe interface.  
Double mutations of the WT GRK5 result in defective phosphorylation 
Next, we generated more single and double mutations of only ET residues in the WT 
GRK5 (see Table 2 for a summary). No new single mutations produced any significant 
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reduction in GRK5 phosphorylation in the constitutive assay. One mutation (R68A) actually 
showed double the activity relative to WT. However, several double alanine substitution 
mutants in various combinations from helices 3, 9, and 10 and the N-terminus significantly 
reduced the activity by 50 – 95 % as compared to WT GRK5; namely L66A-H38A, F166A-
E514A, P61-F166A, L66A-F166A, L66A-E514A, F166A-Q172A, F166A-W173A, Q172A-
L176A, and L66A-P37A (Figure 11). Of note, some of these mutations are within helix 9 
alone; e.g., F166A-Q172A. Most of these residues side chains are on the same face of 
helices 3 and 9, and would be exposed if helix 11 was lifted away. In contrast, mutants 
P61A-Q69A and F166A-Q69A showed no significant effect on GRK5 activity, this is 
consistent with the fact that Q69 side chain is directed away from helices 3, 9, and 11 
interfaces. These results demonstrated that multiple hits were required to sufficiently affect 
activity. 
 
Figure 11. Effect of GRK5 mutations on constitutive β2AR GRK site phosphorylation. 
WT-β2AR cells were transiently transfected with WT or mutant GRK5. After 48 hours, cells 
were solubilized, and constitutive phosphorylation of the β2AR measured as described in the 
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legend to Figure 10. Several double mutations showed significant decrease in GRK site 
phosphorylation (*** p < 0.001 or * p < 0.05 by One-way ANOVA). The data are means ± 
SEM of at least four experiments performed in duplicate. Representative Western blots are 
shown next to the graph. 
 
As important controls, we showed that neither expression levels (Figure 12A) nor 
membrane localization of the defective GRK5 mutants were significantly altered (Figure 
12B). 
 
Figure 12. Expression levels and locale of mutant GRK5. A. GRK5 mutant expression 
levels. WT-β2AR cells transiently overexpressing WT or mutant GRK5 (150 ng cDNA 
plasmid / 35 mm well) were processed as described in the legend to Figure 10.  Data shown 
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represent WT and mutant GRK5 expression levels as quantified from western blots using 
anti-GRK5 antibody, and are given as percent of WT GRK5. Data are means ± SEM of at 
least four experiments (*** p<0.001 by One-Way ANOVA). B. Distribution of WT and 
mutant GRK5 in membrane versus cytosol fractions. WT-β2AR cells were transiently 
transfected with either pcDNA3.1+ (Control), GRK5-WT or mutants (8 µg cDNA plasmid / 
100 mm plate). After 48 hours cell lysates were centrifuged at 600 × g for 5 min and 
supernatant fraction centrifuged at 21K × g for 10 min. The 21K pellet was washed twice 
and solubilized. Equivalent fractions of the lysate, supernate and 21K pellet were run on the 
SDS-PAGE and western blots performed with GRK5 antibody. 
 
 
Furthermore, we found that overexpression of these mutants did not inhibit ISO 
stimulation of β2AR GRK site phosphorylation by endogenous GRKs, implying they lack 
dominant negative activity (Figure 13). Moreover, as a further test of dominant negative 
activity, we performed transient cotransfection of the β2AR with WT or mutant GRK5 in 
COS7 cells. This was followed by treatment of HEK293 cells with carrier or by stimulation 
at low ISO concentration (10 nM) for 2 min. While the mutant GRKs showed much reduced 
constitutive phosphorylation without stimulation as expected, we surprisingly observed a 
significant increase over the background in ISO-stimulated β2AR phosphorylation with the 
mutants similar to WT GRK5 (Figure 13A). As a control, the dominant negative GRK5-
K215R (49) did not show any increase in constitutive phosphorylation; however, it also 
showed no dominant negative activity against ISO stimulation. Interestingly, all of these 
mutants with the exception of L66A-P37A showed a slow moving GRK5 band which was 
previously suggested by Benovic’s group to be caused by autophosphorylation of GRK5 
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(61) (Figure 11). This result suggests that autophosphorylation was not altered by mutants 
other than L66A-P37A. However, we also found in a further control that the mutation 
(S484A-T485A) that should eliminate activity according to Benovic’s study (46, 79) also 
caused constitutive phosphorylation of the β2AR as well as phosphorylation of Rho* (Figure 
14). These controls, in particular the result with the co-transfection with the β2AR and 
GRKs, were critical as they argue against any major conformational change due to the 
mutations. 
 Ideally mutant activity should have been measured in WT- β2AR cells with agonist-
stimulation of the receptor. But because of the rapid and complete agonist-stimulated 
phosphorylation by endogenous GRKs, any additional activity of overexpressed GRK would 
be masked. Remarkably, levels of endogenous GRK2, 5, and 6 in WT- β2AR cells are ~ 200 
fold over that of the receptor (86), consistent with the rapid phosphorylation observed upon 
ISO stimulation. 
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Figure 13. Effect of GRK5 mutations on ISO-stimulated β2AR GRK site 
phosphorylation. A. COS7 cells were transiently transfected with either Flag-β2AR (500 ng 
/ 35 mm well) alone (Control) or Flag-β2AR and WT or mutant GRK5 (150 ng). After 48 
hours, cells were treated with 10 nM ISO (filled bars) or the carrier AT (open bars) for 5 
min, solubilized, lysates were run on SDS-PAGE, probed with anti-pS355, 356, and then 
stripped and reprobed with anti-C-Tail, and with anti-GRK5. The data were normalized to 
the total receptor levels and GRK5 levels (except for the Control) and are means ± SEM of 2 
experiments. Representative Western blots are shown next to the graph. B. WT- β2AR cells 
were transiently transfected with WT or mutant GRK5 (150 ng / 35 mm well). After 48 
hours, cells were treated with 100 nM ISO for 2 min, and processed as described above. 
Representative western blots are shown. Mutations did not affect ISO-stimulated 
phosphorylation of S-(355,356)  
 Figure 14. Effect of mutant GRK5 (S484A-T485A) on β2AR and Rho* 
phosphorylation. A. Constitutive phosphorylation of the β2AR. WT-β2AR cells transiently 
overexpressing WT or mutant GRK5 (150 ng cDNA plasmid / 35 mm well) were processed 
as described in the legend to Figure 10.  Western blots using anti-pS-(355,356), anti-C-Tail, 
and anti-GRK5 antibodies are shown. B. Phosphorylation of Rho*. WT or mutant GRK5 
solubilized from 21K fractions (5-10 nM) was incubated with Rho (4 µM), all samples are 
with light-activated with the exception of the WT GRK5 labeled dark. The control 
represents solubilized 21K membranes from cells transfected with only the empty vector 
(pcDNA3.1+). The autoradiogram and GRK5 levels are shown. Mutation of the 
autophosphorylation sites (S484, T485) did not alter β2AR constitutive phosphorylation or 
Rho* phosphorylation. 
 
2.3.3.3 Effects of WT and mutant GRK6 
Since we and others have shown that GRK6 also plays a role in β2AR 
phosphorylation, we examined the effects of equivalent mutations in GRK6. The 
evolutionarily important cluster we identified in the RH terminal subdomain is shared by all 
the GRKs; therefore we expected that the results obtained with mutant GRK5 would carry 
over to the other members of the family. Single and double mutations similar to those in 
GRK5, as well as some novel combinations, were generated in GRK6, and their activity 
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assessed in the constitutive assay. Expectedly, key double mutations within helices 3 and 9 
significantly reduced (75-90%) the constitutive phosphorylation of the β2AR; namely 
Y166A-L66A, L66A-Q172A, Y166A-Q172A, Y166A-L176A, and Q172A-W173A (Figure 
15). Expression of most of the GRK6 mutants was reduced by ~ 20-40% relative to WT 
GRK6, and two mutants, Q172A and Q172A-L176A failed to be expressed and could not be 
assayed. Mutant L66A-R69A did not affect significantly β2AR constitutive phosphorylation. 
 
Figure 15. Effect of GRK6 mutations on constitutive β2AR GRK site phosphorylation. 
WT and mutant GRK6 were expressed in WT-β2AR cells and constitutive phosphorylation 
of the β2AR measured as described in the legend to Figure 10. The data were normalized to 
the total receptor levels and GRK6 levels. The data are means ± SEM of four experiments 
performed in duplicate (*** p < 0.001 by One-Way ANOVA). Inset: Representative 
Western blots. 
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2.3.4 Phosphorylation of light-activated rhodopsin 
To further explore the activity of GRK5 and 6 mutants, we examined the effects of 
WT and mutant GRK5 and 6 on phosphorylation of light-activated rhodopsin (Rho*). This 
in vitro assay (89) has the important advantage that it allows observation of agonist-
stimulation of a GPCR (in this case the agonist is light activated trans-retinal). While this 
assay is not of physiological relevance it has been the standard in the field for its 
convenience. Rhodopsin is present at extremely high levels in ROS, and relatively large 
amounts of ROS membranes can be isolated from bovine retina. This assay would provide 
further support for the effects of mutations on agonist-induced GPCR activation of 
phosphorylation. 
2.3.4.1 Effects of WT and mutant GRK5 
For the rhodopsin assay, we transiently overexpressed WT and mutant GRK5 in WT-
β2AR cells (30-50 fold). We then either isolated the 21K membrane fraction from which 
GRKs were solubilized, or directly solubilized the intact cells followed by partial 
purification by step elution from a SP-sepharose column (79, 132). Expression of the 
mutants in 100 mm plates was generally lower than that of WT GRK5 in the 21K membrane 
fraction, and most of the mutants showed low recovery in the purification process. To 
circumvent this problem we used the 21K solubilized GRKs for most assays. Levels of 
GRK5 expression were estimated by westerns  by comparison to a standard curves 
generated using GST-GRK5 run on the same gels (86). Levels so measured were adjusted 
such that approximately equivalent amounts of WT and mutant GRK were used in the 
rhodopsin assay.  
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Our findings demonstrate that all of the key double mutants that showed no 
constitutive phosphorylation of the β2AR, showed even more reduced activity (92-98 %) in 
inducing light-activated rhodopsin phosphorylation relative to WT GRK5. Mutants such as 
P61A-Q69A that were active in the constitutive assay showed robust activity (Figure 16). 
Important controls were also performed demonstrating that no activity was detected with 
endogenous GRKs isolated from cells that were transfected with only the empty vector. 
Moreover, no constitutive phosphorylation of dark-adapted rhodopsin was observed with 
either increased Rho up to 32 µM, or increased levels of GRK5 up to 40 fold higher (Figure 
17), consistent with 11 cis- retinal acting as an inverse agonist (133). 
 
Figure 16. Effect of GRK5 mutations on Rho* phosphorylation. WT and mutant GRK5 
were expressed in WT-β2AR cells, solubilized from the 21K membrane fractions (5-10 nM 
GRK5) and assayed as described in Methods. All the data shown are with light-activated 
rhodopsin with the exception of the WT GRK5 labeled dark. The control represents 
solubilized 21K membranes from cells transfected with only the empty vector 
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(pcDNA3.1+). The reaction mix was run on SDS-PAGE and the autoradiogram was 
developed. Data show the percent activity of mutant GRK5 as compared to WT GRK5 and 
normalized to GRK5 expression levels. Quantitation was performed by use of Molecular 
Dynamics Storm Phosphorimager. The data are means ± SEM of at least three experiments 
performed in duplicate. One-Way ANOVA statistical analyses were determined (*** p < 
0.001). Inset: Representative autoradiogram and GRK5 expression levels. 
 
 
Figure 17. Effect of increased Rho and GRK5 concentrations on Rho phosphorylation. 
A. WT GRK5 solubilized from 21K fractions (~ 6 nM) was assayed for its phosphorylation 
of Rho in the absence (–) or presence (+) of light with increasing concentrations of Rho (0 – 
32 µM). B. WT GRK5 (0 – 120 nM) was incubated with Rho (4 µM), and Rho 
phosphorylation was assessed in the absence or presence of light. Autoradiograms are 
shown; no constitutive phosphorylation was detected with either increasing Rho or GRK5 
concentrations. 
 
2.3.4.2 Effects of WT and mutant GRK6 
Similarly to GRK5, WT and mutant GRK6 were transiently overexpressed in WT-
β2AR cells, and 21K membranes fractions prepared and assayed for their activity in vitro 
with light-activated rhodopsin. The results shown in Figure 18 further support our findings 
in the constitutive assay, as all the double mutants that were inactive in the constitutive 
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assay, failed to phosphorylate Rho* by > 95%. Interestingly, the full activity of mutant 
L66A-R69A in the constitutive assay was not retained in the rhodopsin assay, as it showed ~ 
75% diminution in Rho* phosphorylation. Our mutagenesis of GRK6 was not as extensive 
as of GRK5, but overall both sets of results are in agreement providing further evidence for 
the importance of these helices in GPCR activation of GRKs. 
 
Figure 18. Effect of GRK6 mutations on Rho* phosphorylation. WT and mutant GRK6 
were expressed in WT-β2AR cells, solubilized from the 21K membrane fractions (~ 5 nM 
GRK6) and assayed as described in the legend to Figure 17. The percent activity of mutant 
GRK6 as compared to WT GRK6 was calculated, and normalized to GRK6 expression 
levels. The data are means ± SEM of three experiments performed in duplicate (*** p < 
0.001 by One-Way ANOVA). Inset: Representative autoradiogram and GRK6 expression 
levels. 
 
 
47 
 
2.4 DISCUSSION 
   
As discussed in the first chapter, previous studies have identified many GRK 
residues and clusters responsible for interaction with GPCRs. These studies showed the 
importance of both the N- and C-termini in localization of the kinase to the plasma 
membrane and subsequently receptor phosphorylation (49, 92, 93, 107). Moreover, it was 
shown very recently that point mutations (GRK2 (V477D), and GRK1 (R191A/K)) within 
the kinase domain severely diminished receptor phosphorylation in vitro (97, 105). Further, 
Tesmer’s group has recently achieved a crystal structure of GRK1 in the active state 
(personal communication) showing that the N-terminus forms an intramolecular interaction 
with the small lobe of the kinase domain. Based on these collective results, Dr.Tesmer has 
proposed that the allosteric site for GPCR interactions may involve both the N-terminus and 
the small lobe of the kinase. However, as yet no direct evidence for this interaction has been 
demonstrated. Further kinetic studies of N-terminal mutations and small lobe kinase domain 
mutations show non-competitive interactions in the rhodopsin assays (97, 106), suggesting 
that this site is unlikely involved in the allosteric activation of GRK by GPCR. It was also 
suggested that the dimer interface observed in the crystal structures of GRK1 and 6 is a 
likely area of protein-protein interactions (73, 74). Thus, although these studies provide 
molecular insights on how GRKs are activated by GPCRs, it is still not clear which sites are 
directly involved in the allosteric activation of GRK and what role the RH domain may play 
in the conformational change to the active state induced by GPCR activation. As discussed 
in the introduction to this chapter it is likely that the interaction sites are complex. 
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In our studies we aimed at determining regulatory domains of GRKs involved in 
allosteric activation of GPCRs, we sought to first identify important residues within the 
GRKs using a computational technique based on evolutionary conservation of proteins.  
To test the importance of the sites identified by ET in activation of GRK, ET 
residues in the RH domain were targeted for site-directed mutagenesis and examined for 
their effects on β2AR and Rho phosphorylation. Through serendipitous study of the KHE-
GRK5, we found four single mutations of this GRK (P61A, L66A, F166A, and E514A) that 
showed marked defects in constitutive phosphorylation of the β2AR. The results obtained 
with the KHE-GRK5 constructs did not carry over when only these single mutations were 
later introduced in the WT GRK5. To further explore this, we pursued multiple double 
mutations of the WT GRK5 in the ET defined clusters and found six double mutations that 
severely reduced GRK5 and 6 activities. These mutations involved residues in helix 9 alone, 
as well as combinations of residues from helices 3 and 9, 3 and 10, and 9 and 10. Further 
mutations involving residues in loop α0-α1 in combination with helix 3 (L66A-P37A and 
L66A-H38A) also significantly reduced GRK5 activity by 50 and 95 % respectively in 
β2AR constitutive phosphorylation and by > 95 % in Rho phosphorylation. To determine 
which preexisting mutant in KHE-GRK5 caused the observed reduction in activity when 
combined with any of the four defective mutants, we found that both R304H and G439E in 
the kinase domain large lobe were required to obtain the reduced activity. While our 
findings demonstrate that the catalytic activity of several double mutants is inhibited in the 
β2AR constitutive assay in intact cell and in the agonist-dependent assay with rhodopsin 
phosphorylation in vitro, we have not yet resolved how the mutants affect kinase activation. 
Possibilities include: 1) disruption of the allosteric binding to the receptor; 2) indirect 
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impairment of the catalytic activity through delocalized effects propagated from the close 
apposition of the RH domain ET clusters to the small lobe of the kinase domain and the N-
terminus; 3) loss of intramolecular interactions such as α3-α9 interaction leading to 
destabilization of the GRK; 4) loss of plasma membrane binding. We have shown that 
mutants expression was not altered in the 21K crude membrane fractions ruling out the 4th 
possibility. However to better characterize the mechanism of action of the mutants; we 
generated peptides mimicking helices 3, 9, and 10 of GRK with the aim of determining their 
ability to inhibit GRK-GPCR interaction. This hypothesis is the main focus of the next 
chapter in this study. 
Interestingly, the single mutant R68A showed a doubling in activity as compared to 
WT GRK5 in the β2AR assay and to a lesser extent in the rhodopsin assay. In the GRK6 
crystal structure R68 appears to form a salt bridge with the ET residue D85 in helix 4 
(Figure 19). Importantly, mutants R68A and D85A in the KHE-GRK5 both caused an 
increase in activity although not significant relative to KHE-GRK5; activity of mutant D85A 
was not further tested in WT GRK5. However we would expect a similar increase activity as 
that observed with R68A. These results suggest that disruption of the salt bridge might cause 
the release of a constraint on the catalytic cleft facilitating its closure, hence an increase in 
activity. Recently, a GRK5 polymorphism Q41L was shown to cause an increase in the 
kinase activity (109). Together, these findings indicate that there may be residues in GRKs 
that when mutated increase the activity. 
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 Figure 19. Representation of the interaction between residues R68 and D85 on helices 3 and 
4 (cartoon diagram (left) and surface representation (right). 
  
Furthermore, our results showed unexpectedly that GRK5 autophosphorylation site 
double mutant (S484A-T485A) had no effect on either the constitutive phosphorylation or 
rhodopsin phosphorylation; this site was previously shown by Benovic’s group to be 
required for both rhodopsin and β2AR phosphorylation. From a personal communication 
with Dr Benovic we found that he had 1) not followed up on this study, and 2) likely used a 
mutant similar if not identical to the KHE mutant we characterized (obtained indirectly from 
his group). Thus at present we feel that the autophosphorylation of GRK5 may not be a 
requirement for activity. Our results will be pursued in future studies. 
  
51 
 
  
 
 
 
 
 
 
 
CHAPTER 3 
DEVELOPMENT OF PEPTIDE INHIBITORS OF THE GPCR-GRK 
INTERACTION 
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3.1 INTRODUCTION 
  
One of the goals of our group is to develop novel inhibitors of GRK-mediated 
desensitization of the β2AR. Our identification of new sites within the GRK RH domain that 
are important for kinase activity provided us with several possible approaches for generation 
of a peptidomimetic inhibitor (22, 83, 106, 117). Also demonstration that a peptide 
mimicking the ET clusters of the RH domain inhibits GRK phosphorylation of GPCRs, 
would further support the relevance of our structure/function findings. Toward these ends, 
we generated a library of peptide mimetics of GRK5 helix 9 based on either straightforward 
mimicry of the helix coupled with alanine scanning, computational design aimed at 
preserving highly ranked ET residues, or chemical modifications that lock the peptide in a 
helix. For screening of the peptides we utilized the rhodopsin phosphorylation assay. A 
number of peptides were found to profoundly inhibit GRK phosphorylation of Rho* with 
IC50s in the range of 10-40 µM. While we have not yet defined the physical site of 
interactions of the peptides, our findings appear to confirm the importance of these sites. 
  
3.2 METHODS 
 
3.2.1 Computational design of peptides  
Daniel Morgan from the Lichtarge group used the peptide builder AGADIR 
algorithm (134) to model peptides on an alpha helix structure based on helix 9 native 
sequence FFDRFLQWKWLE with ET residues shown in red. Analysis of the isolated α9 
sequence by AGADIR predicted less than 5% helical propensity when it is in solution as a 
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monomer, as opposed to the stabilized helical conformation in the crystal structure. This 
suggests that this fragment might fold differently than in the native protein, thus it would be 
less active alone than as a part of the whole structure. As an alternative, we sought to 
generate peptides that were more likely to fold into helices, and with increased solubility. To 
build such peptides, an algorithm was created by Drs Morgan and Lichtarge such that the 
non-ET residues were substituted randomly until helicity was maximized. Peptides including 
14-16 residues were generated following the sequence x-x-x-F166-x-x-R169-x-x-Q172-
W173-x-x-L176-x, the free residues ‘x’ were replaced over 500 iterations under the 
condition that a replacement was accepted only if helicity increased, or until a helicity of 
85% was reached. Peptide Builder generated a list of peptides to which scores for helicity, 
hydrophobicity or charge are assigned. From this list three peptides (1, 2, and 3) were 
selected (Table 3). Models of these peptides were created using PyMol (DeLano 2002), and 
energy was minimized using MESHI (135). The relative positions of the residues in the 
modeled peptides were similar to those of the native helix 9 (Figure 20). Peptides 1-5 were 
purchased from Genemed Synthesis, Inc. (San Antonio, TX). All of the other peptides were 
synthesized by Dr. John McMurray’s group at the UT M.D.Anderson Cancer Center. 
Table 3. Sequences and modifications of the helix 9, GRK5/6 N-Ter, and il-1 β2AR 
peptides 
Peptide Sequence Modification Result 
Designed by Peptide Builder 
1       EFDRRWRQWRELWLR Modified sequence except for ET residues *** 
1AA    Ac-EFDRRWRQWRELWLR-NH2 (AA) Acetylated and amidated peptide 1 *** 
2       DFEERRRQWLILYR Modified sequence except for ET residues * 
2AA    Ac-DFEERRRQWLILYR-NH2 (AA) Acetylated and amidated peptide 2 – 
3     EEYFKRRWEQWYKLY Modified sequence except for ET residues * 
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Native sequence of Helix 9 
4        YFNRFLQWKWLE Unmodified GRK6 α9 (166-177) *** 
5     Ac-FFDRFLQWKWLE-NH2 Acetylated and amidated GRK5 α9 (166-177) *** 
6 Ac-SNleFFDRFLQWKWLER-NH2 Acetylated and amidated GRK5 α9 (164-M165Nle-178) *** 
Constrained peptides 
7 Ac-SNleFFDRELQWKWLER-NH2 E170 side chain – K174 side chain bridge (underlined) *** 
8 Ac-SNleFEDRFKQWKWLER-NH2 E167 side chain – K171 side chain bridge (underlined) ** 
Mutant peptides 
F166A Ac-SNleAFDRFLQWKWLER-NH2 Mutation F166A in peptide 6 * 
R169A Ac-SNleFFDAFLQWKWLER-NH2 Mutation R169A in peptide 6 **** 
Q172A Ac-SNleFFDRFLAWKWLER-NH2 Mutation Q172A in peptide 6 *** 
W173A Ac-SNleFFDRFLQAKWLER-NH2 Mutation W173A in peptide 6 * 
L176A Ac-SNleFFDRFLQWKWAER-NH2 Mutation L176A in peptide 6 *** 
Truncated peptides 
A  Ac-NleFFDRFLQWKWLER-NH2 GRK5 α9 (M165Nle-178) *** 
B   Ac-FFDRFLQWKWLER-NH2 GRK5 α9 (F166-178) *** 
C Ac-SNleFFDRFLQWKWLE-NH2 GRK5 α9 (164-M165Nle -177) * 
D Ac-SNleFFDRFLQWKWL-NH2 GRK5 α9 (164-M165Nle-176) *** 
E Ac-SNleFFDRFLQWKW-NH2 GRK5 α9 (164-M165Nle-175) *** 
F Ac-SNleFFDRFLQWK-NH2 GRK5 α9 (164-M165Nle-174) – 
G Ac-SNleFFDRFLQW-NH2 GRK5 α9 (164-M165Nle-173) * 
Additional peptides 
N-Ter MELENIVANTVLLKAR-NH2 Unmodified GRK5/6 N-terminus (1-16) *** 
il-1 β2AR AKFERLQTVTNYFITSE Truncated and modified β2AR il-1 (59-74E) (83) *** 
ET residues are shown in bold and red. 
Mutated residues are shown in bold and underlined. 
The linked residues are shown in blue. 
Peptides 6, 7, and 8: Nle was substituted for M165 to avoid sulfur oxidation. 
***: > 65 % inhibition, **: 45-65 % inhibition, *: 25-45 % inhibition, –: no effect 
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 Figure 20. Model of the Peptide Builder designed peptides. A. Structure of the native 
helix 9 of GRK5/6, shading shows the buried residues in the native structure. B-D. Peptides 
1, 2, and 3 were modeled using PyMol, the relative positions of ET residues (red) were 
similar to those of the native helix. White residues were randomly selected using Peptide 
Builder (136-138) to enhance helicity and solubility. 
 
3.2.2 Synthesis of chemically modified peptides 
In order to generate peptides with higher helical propensity, and near native sequence 
that would mimic the bioactive conformation, Subir Sabui and Dr. McMurray designed and 
synthesized constrained analogues of GRK5 helix 9 by introducing side chain to side chain 
bridges (139, 140) as shown in Figure 21 and listed in Table 3 (peptides 7 and 8). Also in 
order to develop peptides with higher affinity, Dr. Richard Hammitt (the McMurray group) 
did a partial alanine scan of GRK5 helix 9 peptide (mutant peptides in Table 3). For controls 
Dr. Hammitt also synthesized a peptide that mimics the N-terminus of GRK5/6 (residues 1-
16) (97), and one that mimics the intracellular loop 1 (il-1) of the β2AR (83). Finally he 
systematically synthesized truncated peptides based on helix 9 sequences to enhance cell 
penetration as listed in Table 3.  
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Peptides 6, 7, and 8 were acetylated on the N-terminus and were synthesized as C-
terminal amides. Polydimethylacrylamide-based PL-DMA resin (Varian, Inc) was treated 
overnight with neat ethylenediamine (141). After thoroughly washing the resin with 
DMF/CH2Cl2, Fmoc-Rink amide linker was added in three-fold excess, as calculated from 
the nominal loading of 1 mmol/g. Coupling was mediated with 3-fold excesses of PyBOP, 
HOBt, and a 6-fold excess of DIEA. On completion of the coupling as judged by negative 
ninhydrin tests, the resin was drained, washed with DMF/CH2Cl2 and CH2Cl2 then dried 
under vacuum and stored. By weight gain, the loading was 0.65 mmol/g. Peptides 6, 7, and 8 
were synthesized in parallel on aliquots of 0.20 g of this resin (0.65 mmol/g, 0.13 mmol) on 
an AAPPTEC 348 multiple synthesizer employing a 16-well reactor block. Fmoc-amino 
acids were added in 6-fold excess and coupling was mediated by DIPCDI/HOBt in 7 ml of 
DMF/CH2Cl2 (1:1). Methionine 165 was replaced by Nle to avoid oxidation of the sulfur 
group. Resins were washed 5× with 7 ml of DMF/CH2Cl2 (1:1) after coupling and 
deprotection steps. Fmoc deprotection was mediated by treatment of the resins for 5 and 15 
minutes with 7 ml of 20% piperidine in DMF. For peptide 7, Fmoc-Glu(OPip)-OH was used 
at position 170 and Fmoc-Lys(Mtt)-OH was used at position 174. For Peptide 8, Fmoc-
Glu(OPip)-OH was used at position 167 and Fmoc-Lys(Mtt)-OH was used at position 171. 
Peptides were acetylated at their N-termini by addition of acetic anhydride on the automated 
synthesizer. On completion of the amino acid chains, these two resins were treated with 1% 
trifluoroacetic acid (TFA) in CH2Cl2 (5×7 ml, 5 min each).  After washing, cyclization was 
achieved by treatment of the resins with 3 equivalents each of diisopropylcarbodiimide and 
1-hydroxybenzotriazole for 20 hr. All three peptides were cleaved from their resins with 
TFA:triethylsilane:H2O (95:2.5:2.5) (142) for 2 hr, the volumes were reduced, the products 
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were precipitated in Et2O and collected by centrifugation and dried. Peptides were purified 
by Sephadex G-25 chromatography (2.5×100 cm) in 0.1 M AcOH followed by reverse phase 
HPLC using gradients of acetonitrile in H2O (both solvents containing 0.1% TFA). All 
peptides were greater than 95% pure and gave the correct mass by ESI TOF mass 
spectrometry. 
 
Figure 21. Sequence of chemically modified GRK5 helix 9 peptidomimetics. Peptides 7 
and 8 analogous to peptide 6 (native sequence of GRK5 α9) were built with side chain to 
side chain bridges to constrain the peptide into a helical conformation. The Bridges are 
located to the back side of the helix relative to ET residues (red). 
 
3.2.3 In-vitro peptide assay 
Peptide mimetics of GRK5 helix 9 and the N-terminus (residues 1-16) as well as a 
peptide mimetic of the β2AR il-1 (83) were designed as described above, and tested for their 
inhibition of GRK5 phosphorylation of light-activated rhodopsin (Rho*). Peptide 
concentrations were calculated based on absorbance at 280 nm. The assay was performed as 
follows: 2 μl peptides dissolved in DMSO (Dimethyl Sulfoxide) were added first to the 
reaction tube on ice such that the final concentration would be 10, 30, or 100 μM. 
Rhodopsin (4 µM or as indicated) was incubated in 20 mM Tris-HCl, pH 7.5, 1 mM EDTA, 
10 mM MgCl2, and 100 μM [γ32P]ATP in a final volume of 32 μl, activated by illumination 
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(475 nm) for 30 sec, and 12 µl was added to each tube. Lastly, SP-sepharose-purified GRK5 
(5-10 nM) or purified 6His-GRK5 (4.6 nM) was added to the tubes in the absence or 
presence of peptides, and incubated at 30 °C for 10 min to induce the phosphorylation. To 
stop the reaction, 4X SDS-sample buffer was added and samples were processed as 
described above. 32P-Rhodopsin bands were quantified by use of a Storm Molecular 
Dynamics Phosphorimager and by direct counting of excised bands. 
 
3.3 RESULTS 
.3.1 Peptide inhibition of GRK5 phosphorylation of light-activated rhodopsin 
re required 
for bot
 
3
We have shown in the previous chapter that key sites in GRK5 and 6 we
h β2AR and Rho* phosphorylation. We identified three helices in the RH terminal 
subdomain that were crucial for GRK5 and 6 activities. Based on these results, we aimed to 
develop peptide inhibitors of GRK activity. Since double mutations in helix 9 consistently 
resulted in a dramatic reduction of GRK phosphorylation of both receptors, this helix was 
selected first for peptide design. Notably, the crystal structure of GRK6 shows that most of  
what appear to be key residues for activity are displayed as a continuous surface on one side 
of helix 9 (Figure 10D). A library of peptides (Table 3), were synthesized and tested for 
their ability to block GRK5 phosphorylation of Rho*. These included first and foremost 
those based on the native sequence of GRK5; peptides 5 (residues 166-177) and 6 (164-
M165Nle-178) and GRK6 peptide 4. Of note, Met165 in peptides 6, 7, and 8 was replaced 
by Nle to avoid oxidation of the sulfur group. Peptides 1, 1AA, 2, 2AA, and 3 were designed 
using a peptide builder algorithm such that ET residues were fixed while the others were 
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selected to increase helicity and solubility. Peptides 7 and 8 were chemically modified such 
that the native sequence of helix 9 was locked into a helical conformation by building side 
chain to side chain bridges.   
Results from assay of 100 µM peptide inhibition of Rho* phosphorylation by 
partially purified GRK5 are shown in Figure 22A. Of the three computationally-designed 
peptides, only 1 and 1AA (acetylated and amidated) showed significant inhibition of ~ 73 
and ~ 86% respectively, indicating that ET residues are sufficient for activity. Peptides 2 and 
3 had much reduced inhibitory activity. The chemically locked peptides 7 and 8 inhibited 
GRK5 phosphorylation of Rho* by ~ 85 and 51% respectively, implying helicity is 
important. Importantly, the native helix 9 peptides 5 and 6 were both active and showed 
significant inhibition of ~ 66 and 82 % respectively. Likewise peptide 4 derived from GRK6 
and which differs in only two residues from that of GRK5 (Y166 and N168 in GRK6 vs. 
F166 and D168 in GRK5), showed similar inhibition as with peptide 6. We then tested the 
inhibitory activity of peptides 1AA, 4, 6, and 7 at concentrations of 10 and 30 µM. No 
significant inhibition was observed at 10 µM with any of the peptides; however at 30 µM 
peptides 1AA, 4, and 6 showed significant inhibition of ~ 45, 40, and 63 % respectively 
(Figure 22B). 
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 Figure 22. Peptide inhibition of GRK5 phosphorylation of Rho*. Illuminated rhodopsin 
was incubated with SP-sepharose-purified GRK5 in the absence (Ctrl) or presence of the 
peptides listed in Table 3. Bsl (basal phosphorylation) refers to samples incubated with non-
illuminated rhodopsin and in the absence of peptide. A. Peptides were used at 100 µM. Data 
shown are means ± SEM for at least three experiments performed in duplicate (*** p < 
0.001, ** p < 0.01, * p < 0.05 by One-Way ANOVA). A representative autoradiogram is 
shown below the graph. B. Peptides 1AA, 4, 6, and 7 were used at 10, 30, and 100 μM. Data 
shown are means ± SEM for three experiments performed in duplicate, except for peptide 4 
(two experiments in duplicate at 10 and 30 μM). P values for peptides 1AA, 4, 6, and 7 at 30 
μM were < 0.01, < 0.01, < 0.001, and > 0.05 respectively by One-Way ANOVA. 
 
3.3.2 Kinetic analysis of peptide 6 inhibition 
To further investigate the mechanism of peptide inhibition, we examined GRK5 
activity with varied concentrations of Rho* (0-25 µM) in the presence of 100 µM peptide 6. 
The nature of inhibition of this peptide appeared mixed competitive/non-competitive (Figure 
23), since we observed a consistent decrease in the Vmax and an increase in the Km. 
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However, confirmation of this result will require more refined kinetics since the data 
showed non-hyperbolic, possibly positively cooperative kinetics at low rhodopsin 
concentration in the absence and presence of the peptide confounding interpretation. Further 
confounding this issue is the inherent nature and complexity of the GPCR-GRK5 
interaction. That is, GPCRs both activate GRKs and are substrates for the enzyme and it is 
not resolved whether the GPCR activating the kinase is in turn phosphorylated only by its 
“private” kinase or must phosphorylate another in the vicinity. While highly purified GRK5 
was used for these experiments, the possibility of further complexity from either 
autophosphorylation or other contaminating kinases is unresolved. Finally phosphorylation 
of rhodopsin by GRK5 is not the native situation, and it is not known whether GRK5 
binding to the ROS discs reflects its in vivo binding to membranes. 
 
Figure 23. Kinetic analysis of peptide 6 inhibition of GRK5 phosphorylation of Rho*. 
Increasing concentrations of Rho* (0 – 25 µM) were incubated with purified 6His-GRK5 
(4.6 nM) in the absence (Ctrl) or presence of peptide 6 (100 µM) for 10 min at 30 ⁰C. The 
experiment shown is representative of four similar experiments each performed in duplicate. 
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Kinetic parameters for the control and peptide treated were as follows: Vmax = 4.0 ± 1.1 and 
1.0 ± 0.1 nmol/mg/min; and Km = 11.7 ± 6.9 and 21.1 ± 4.0 μM respectively. An 
autoradiogram is shown below the graph. 
 
3.3.3 Specificity of peptide inhibition 
Furthermore, since both peptides 4 and 6 inhibited GRK5, we tested their effects on 
GRK6 activity. Surprisingly, we found that peptide 6 (based on GRK5) did not inhibit 
GRK6 phosphorylation of Rho*, whereas peptide 4 which is derived from GRK6 was active 
(Figure 24). This indicates specificity for GRKs and suggests that the site of action is on 
GRK rather than on rhodopsin, since if it interacts with the Rho* one would expect similar 
inhibition of both GRKs. 
 
Figure 24. Peptides 4 and 6 inhibition of GRK phosphorylation of Rho*. Peptides 4 and 
6 (100 μm) were incubated with Rho* (4 μM) and either GRK5 (open bars) or GRK 6 (filled 
bars) for 10 min at 30 ⁰C. Data shown are the means ± SEM for three experiments 
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performed in duplicate and normalized to % of control. A representative autoradiogram is 
shown below the graph. 
 
3.3.4 Effects of mutant peptide 6 on GRK5 phosphorylation of Rho* 
Because the native sequence peptide 6 (100 µM) showed > 80 % inhibition of Rho* 
phosphorylation by GRK5, and to further explore the importance of ET residues, we 
designed another set of peptides by replacing each ET residue in peptide 6 by an alanine as 
shown in Table 3. The test of these peptides’ activity revealed interesting features as shown 
in Figure 25A. We found that mutant peptides F166A and W173A showed much reduced 
activity relative to peptide 6, however their inhibition of phosphorylation was still 
significant as compared to the Control (~ 42 and ~26 % respectively), this suggest these 
hydrophobic residues are important for inhibition. Peptides R169A, Q172A, and L176A 
showed inhibitions of ~ 98, 95, and 74 % respectively; interestingly alanine substitution of 
the charged residue R169 showed a somewhat greater inhibition relative to peptide 6, and 
inhibited with an IC50 of ~ 10 µM (Figure 25B). This result was exciting and was a 
considerable improvement over the WT peptide 6 (IC50 of ~ 30 µM).  
In recent studies the N-terminal domain of GRK1 and 2 was shown to play an 
important role in the phosphorylation of rhodopsin (97), so we tested the inhibitory activity 
of the GRK5 N-terminus peptide (residues 1-16) as well as a peptide derived from the il-1 of 
the β2AR (residues 59-74E) which was previously shown to inhibit GRK2, 3, and 5 
phosphorylation of Rho* (83). These peptides showed inhibitions of ~ 85 and 97 % 
respectively, indicating these sites are also important in GPCR phosphorylation. These 
peptides will be useful in the future for comparative studies with the helix 9 peptides. 
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 Figure 25. Mutant peptide inhibition of GRK5 phosphorylation of Rho*. Illuminated 
rhodopsin was incubated with SP-sepharose-purified GRK5 as described in the legend to 
Figure 22. A. Peptides were used at 100 µM. Data shown are means ± SEM for at least three 
experiments performed in duplicate, except for the N-Ter peptide (two experiments in 
duplicate) (*** p < 0.001, ** p < 0.01 by One-Way ANOVA). B. Peptides 6, R169A, and 
Q172A were used at 10, 30, and 100 μM. Data shown are means ± SEM for three 
experiments performed in duplicate. P values for all three peptides at 30 μM were < 0.001, 
and at 10 µM P < 0.01 for R169A by One-Way ANOVA. Representative autoradiograms are 
shown below the graph. 
 
3.3.5 Preliminary results of truncated peptide effects 
Ideally, peptide activity should be assessed in an intact cell assay for their inhibition 
of β2AR phosphorylation by GRK5 or 6. However, this mode of assay necessitates 
permeable peptides, hence why we opted for the cell-free rhodopsin assay. In the early 
stages of peptide studies, we found a small inhibition by peptide 6 of β2AR phosphorylation 
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in the 21K membrane fractions by endogenous GRKs (86). Unfortunately results were 
variable, perhaps due to the inability of peptides to penetrate the membrane vesicles. For 
future studies we are planning to reinvestigate this assay. Also, to circumvent the 
permeability  problem, one could use cell penetrating systems to deliver peptides into the 
cell e.g. Chariot, PULSin (143) or peptide transduction domains; e.g., TAT 
(YGRKKRRQRRR), poly-arginine (144, 145). Another approach is to work on making the 
peptide shorter since it is well established the shorter peptides generally have enhanced 
permeability. Preliminary results with several shortened peptides based on peptide 6 
(peptides A-G listed in Table 3) are shown in Figure 26. Additional modifications of the 
peptides might be required to further confirm these results.  
 
Figure 26. Truncated peptide inhibition of GRK5 phosphorylation of Rho*. Illuminated 
rhodopsin was incubated with SP-sepharose-purified GRK5 as described in the legend to 
Figure 22. The autoradiogram is from for one experiment.. Peptides were used at 100 µM. 
 
 
3.4 DISCUSSION 
 
We aimed to develop a specific peptide inhibitor of GPCR activation of GRKs based 
on mimicking sites in GRK that are important for interaction with and or phosphorylation of 
GPCRs. Thus we reasoned that we should first search for residues in GRKs that were 
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required for GPCR phosphorylation. In chapter 2, we showed that helices 3, 9, and 10 in the 
RH terminal subdomain formed an evolutionarily conserved cluster; and that double 
mutations of numerous residues within this cluster impaired GRK5 and 6 phosphorylation of 
both β2AR and Rho* in intact and cell-free assays respectively. Based on these results we 
designed peptide mimetics of GRK5 helix 9 that would potentially disrupt GRK-GPCR 
interaction. These peptides included: 1) unmodified helix 9 sequence; 2) modified sequences 
where only ET residues were kept unchanged; 3) peptides chemically locked into helical 
conformation; and 4) truncated peptides.  
Results from assays of peptide inhibition of GRK5 phosphorylation of Rho* showed 
that the native helix 9 peptides 5 and 6 derived from GRK5, as well as peptide 4 derived 
from GRK6, inhibited  ~ 66-83 % at 100 µM and displayed IC50s around 30 µM. We have 
not yet performed circular dichroism to determine the helicity of these peptides; however, 
the peptides that were locked into a helical conformation, peptides 7 and 8, also showed 
significant inhibitions of GRK5 activity, suggesting that helicity is important. We also found 
that the peptide builder-designed peptide 1 whether acetylated and amidated at the N- and C-
termini, significantly reduced GRK5 phosphorylation of Rho*, indicating that the top-
ranked ET residues retained on one face of the helix may be critical. The other peptide 
builder-designed peptides 2 and 3 showed much reduced activity as compared to peptide 1, 
perhaps due to the introduction of several charged residues such as Glu which likely 
interfere with the binding of the peptide.  
Results from the alanine screen of ET residues in peptide 6 demonstrated that 
substitution of the two hydrophobic residues F166 and W173 markedly reduced peptide 
activities as compared to the WT peptide. Whereas substitution of the charged residue R169 
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resulted in a peptide with the highest affinity yet, showing an IC50 of ~ 10 µM and near 
complete inhibition at 100 μM. This experiment indicates that hydrophobic residues are 
necessary for peptide binding, and is congruent with results obtained with peptides 2 and 3 
into which charged residues were introduced. On the other hand it possibly increases the 
probability of the peptide binding hydrophobic pockets in either rhodopsin or GRK that may 
not be involved in the allosteric activation. 
The findings of kinetic studies of peptide 6 inhibition of GRK5 phosphorylation of 
Rho* were ambiguous since it appeared that the peptide altered both the Km and the Vmax 
for Rho*, suggestive of a mixed competitive/non-competitive inhibition. One problem with 
the kinetic study is that the increase in activity with increasing rhodopsin concentrations was 
clearly not hyperbolic. This is not a straightforward system for kinetic studies, not the least 
of which is that GRK5 is not the physiological regulator of rhodopsin. To further explore the 
site of action of peptide inhibition, we tested whether these peptides would inhibit GRK6 
activity. We found that peptide 6 derived from GRK5 inhibited GRK5, but not GRK6, while 
the peptide derived from GRK6 inhibited both GRKs, demonstrating some specificity for the 
GRK5 based peptide. These data coupled with the apparent mixed nature of inhibition by 
peptide 6, suggest that the peptides may act on GRK rather than the receptor, possibly by 
altering the interaction between helices 3 and 9. Further investigations will be required to 
determine the site or sites of peptide binding. 
 As already shown and discussed, helix 9 based peptides obviously block the catalytic 
activity of GRK, and although this helix is away from the catalytic site, the effect might 
propagate through the small lobe of the kinase. Potential role for helices 3 and 10 and other 
conserved sites within the RH domain need to be examined. Furthermore, we showed that 
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GRK5 N-terminus (residues 1-16) based peptide inhibited GRK5 phosphorylation of Rho* 
confirming and extending a very recent report of GRK2 inhibition by its N-terminal peptide. 
Clearly the N-terminus plays a role in activation by GPCR (89, 97, 106); however kinetic 
studies to date suggest that its action is non-competitive. This appears to be incompatible 
with it acting at the allosteric site in competition with receptor. The crystal structure of 
GRK6 in the active state shows that the N-terminus folds over the small lobe of the kinase 
domain (a key residue being R190). This domain lies between the two kinase domain lobes, 
and is in apposition to the active site tether (Dr. John Tesmer, personal communication). 
This supports the idea that the GRK N-terminus likely stabilizes the active state through 
intramolecular interactions, but does not resolve its role in the allosteric binding to the 
GPCRs.  
Complementing these findings our results suggest that the RH domain contributes to 
stabilizing the active state of the kinase. Possible mechanisms of helix 9 peptide inhibition 
include: 1) peptide binding to the GRK allosteric site preventing GRK association with the 
receptor; 2) peptide binding to the receptor perhaps in a hydrophobic pocket similar to what 
has been shown for transducin C-terminal peptide binding to rhodopsin; 3) peptide 
interactions with helix 3 and 10 that prevent the transition to the active state by delocalized 
effects; and 4) peptide alteration of GRK localization to the plasma membrane. Whatever 
the mechanism of helix 9 peptide inhibition proves to be, we believe that the peptides 
developed thus far will serve as lead agents for future development of a GRK inhibitor with 
higher potency and specificity. Hopefully these will be suitable for use as probes of the roles 
of GRK phosphorylation in β2AR desensitization in cells. 
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CHAPTER 4 
GENERAL SUMMARY 
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4.1 CONCLUSIONS 
 
One of the most critical aspects of GPCR regulation is that immediately following 
agonist-activation, the GPCRs are desensitized. This process is crucial for maintenance of 
homeostasis and cell function. Our group’s long term goal is to establish the basic 
mechanisms of desensitization of the β2AR and the development of pharmacological means 
of intervening in the desensitization events. GRKs play a central role in regulating β2AR 
signaling by phosphorylating the agonist-stimulated receptor which then promotes profound 
desensitization. As such, understanding both the mechanisms of GRK activation and 
phosphorylation of GPCRs and the varied roles in physiology are important. Therefore, the 
development of inhibitors of the GPCR-GRK interaction is of considerable interest, both as 
a tool for the study of their actions, as well as ultimately for their use in the treatment of 
disease states; such asthma where the loss of β2AR response by desensitization is limiting 
for drug efficacy.  
The goals of this study were to probe the nature of the allosteric GRK activation by 
GPCRs, and to develop peptide inhibitors based on knowledge of and mimicry of the GRK-
GPCR interaction domains. Towards this endeavor, we merged computational, biochemical, 
and pharmacological approaches made possible by our collaborations with both the 
Lichtarge (ET study) and the McMurray (peptide chemistry) groups. We first identified key 
functional residues within GRK’s RH and kinase domains employing the evolutionary trace 
methodology. Top-ranked residues were generated by using Difference trace such that traces 
of both the RGS and AGC kinase superfamilies were subtracted from those of the GRK 
subfamily to isolate GRK-specific key residues. By mapping Difference trace results onto 
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the 3-dimentional structure of GRK6, clusters of important residues were revealed in both 
domains presumably important for protein-protein interfaces. We focused this study on the 
RH domain cluster around helices 3, 9, and 10. An alanine scan of the key residues was 
performed involving over 50 single and double mutations. Biochemical assays were then 
performed to determine effects of these mutations on GRK5 and 6 activities. We assessed 
both the constitutive phosphorylation of the β2AR GRK site in an intact cell setting using 
HEK293 cells stably overexpressing the receptor, and the phosphorylation of light-activated 
rhodopsin in vitro by GRK constructs. Consistent with the ET results, our mutagenesis 
strategy demonstrated that the structural integrity of helix 3, 9, and 10 cluster was crucial; 
and numerous double alanine substitutions within helix 9 alone, helix 3 and 9, helix 3 and 
N-Terminus, and helix 3 or 9 and 10 severely reduced GRK activity.  No point mutations 
altered GRK activity with the exception of R68A which exhibited a doubling in activity in 
the constitutive assay. Importantly, these mutations did not alter membrane binding. For 
reasons not understood, they did not exhibit dominant negative activity against ISO-
stimulated β2AR phosphorylation by endogenous GRKs. In summary, while our 
mutagenesis study identifies a novel domain required for activity, we have not yet resolved 
the role it plays in GRK activation. Possibilities include 1) disrupting direct contact points 
with the receptor, thus altering the allosteric binding site; 2) blocking signal propagation 
from GPCR binding to kinase activation, such that this domain bridges the binding and 
catalytic domains; and 3) disruption of contacts with neighboring helices leading to a 
destabilization of the tertiary structure of the kinase. The latter requires a major 
conformational change leading to a catalytically dead or mostly dead kinase. Based on 
several recent studies it has been proposed that the receptor interacts with the N-terminus of 
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GRKs and the small lobe of the kinase domain; however kinetic studies of mutant GRK 
characteristics at present are unresolved. Since this region lies close to the ET cluster we 
identified, it remains difficult to make any strong conclusions on the specific residues 
involved in the GPCR-GRK interaction. 
In the second phase of this work we used our findings on the role of the RH cluster 
to develop peptide mimetics that would potentially disrupt the β2AR-GRK5 interaction.  
Based on these findings that a number of helix 9 mutations alone or in combinations with 
close regions reduced GRK activity, peptide mimetics of helix 9 were designed and assayed 
for their ability to inhibit GRK phosphorylation of light-activated rhodopsin. Peptides were 
synthesized as follows: 1) the native sequence of both GRK5 and 6; 2) peptides designed by 
Peptide Builder such that ET residues were preserved while others modified to optimize 
helicity and solubility, 3) chemically locked peptides into helical conformation; 4) alanine 
scan of ET residues sequences, and 5) shortened peptides. Using these approaches we found 
the following: 1) the native helix 9 sequence of GRK5 and 6 inhibited GRK5 
phosphorylation of Rho* by 65-98 % at 100 μM with IC50s of 30-40 μM; 2) a 
computationally designed peptide preserving several key ET residues was effective; 3) a 
peptide locked into a helix inhibited GRK5; 4) based on alanine scanning that the native 
peptide of GRK5 with Arg169 converted to alanine gave us our most potent inhibitor (IC50 ~ 
10 μM); 5) the hydrophobicity of the peptide was important; 6) the kinetics of peptide 
inhibition was complex and not clearly competitive or non-competitive; 7) there may be 
some specificity in inhibitor action as the GRK5 peptide did not block GRK6 
phosphorylation; and 8) truncation of the LER from the C-Terminus did not appear to 
diminish activity suggesting we can reduce peptide size. Thus we have successfully 
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generated a unique inhibitor fulfilling one of our goals. This work appears to confirm the 
mutagenesis findings on the importance of the RH domain cluster. However, we are unsure 
as to the mechanism; that is, do the peptides bind the receptor or the GRK. The kinetics and 
specificity (points 6 and 7 above) seem to indicate binding to the GRKs. If as we propose, 
the peptides bind to the GRK, it seems unlikely energetically that the peptides can bind and 
displace the α3-α9 interaction. The hydrophobicity of our most potent peptide (R169A) 
raises the possibility that it binds to a matching hydrophobic site on the GRK. In order to 
tease out how the peptide inhibitor binds GRK and to further pursue the possibility that 
receptor binding is directly affected, we propose the following experiments. 
 
4.2 FUTURE DIRECTIONS 
 
 As discussed above, though we have discovered a novel role for the RH terminal 
subdomain domain of GRK critical for activation by GPCRs through mutagenesis of 
evolutionarily important sites and functional assays; both mechanisms of inhibition of 
receptors phosphorylation by RH domain key mutants and helix 9 peptidomimetics effects 
have not been resolved. To address the potential mechanisms for mutant actions, the 
following experiments are being considered: 1) examine whether GRK mutations affect 
direct binding to the receptor by FRET or BRET methodologies. We have previously shown 
the tight association of the β2AR with GRK5 using BRET (86). If the mutations affect the 
allosteric binding then FRET/BRET signals should be reduced as compared to WT GRK5. 
However the mutations could alter the structure through delocalized effects that indirectly 
alter binding of GPCRs; 2) determine the association of the β2AR with mutant GRK5/6 
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through immunoprecipitation. This has not been previously accomplished because of the 
tight membrane localization of both proteins of interest. Thus it would require finding 
conditions that would preserve the association with mild detergent solubilization. Recently it 
was reported that the serotonin receptor 5HT4-R was able to bind GRK5 through the use of 
a procedure involving binding of the receptor to an affinity column (52); 3) analyze mutant 
activities against increased concentrations of Rho* to determine Km vs. Vmax effects. Pure 
competitive kinetic i.e. an increase in Km would imply disruption of the activation binding 
site. A decrease in Vmax would imply a reduction in catalytic activity; 4) measure the 
“basal” activity of the mutants through assays of non-receptor substrates phosphorylation, 
autophosphorylation, and ATP binding to the active site to sort out direct effects on catalytic 
activity. This will help resolve delocalized effects which would result in reduced activities; 
5) extend the mutagenesis/functional assays to the other clusters identified by ET (N-
Terminus and the kinase domain small lobe), as well as to GRK1 and 2 representatives of 
the two other subfamilies. These studies should help refine the possibility as proposed by 
Tesmer that the N-terminus directly interacts with the receptor; 6) develop in vitro assays of 
reconstituted highly purified β2AR and GRK5 constructs to assess the activity of the 
mutants for phosphorylation of the agonist-stimulated β2AR. 
 To further explore the nature of helix 9 peptides inhibition, we propose to: 1) 
improve their affinity/potency through alanine scanning of ET residues, chemical 
modifications, truncations, and permeability modifiers; 2) establish the binding sites of 
peptide inhibitors by generating photolabeled peptides; 3) compare and contrast kinetics of 
inhibition of helices 3, 9, and 10,  N-Terminus, il-1 β2AR based peptides to determine 
whether their effects are additive, competitive or mixed; 4) optimize conditions for the use 
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of the cell-free 21K membrane fraction and/or the intact cell assay to test for the inhibition 
of ISO-stimulated β2AR phosphorylation by endogenous GRKs. This would require 
peptides with enhanced permeability through truncations, introduction of transduction 
domains, or use of peptide delivery agents; 6) determine “basal” phosphorylation of non-
receptor substrates. If the peptides are acting on GRK, one would expect an inhibition of the 
substrate phosphorylation; 7) characterize specificity of the peptides for the other GRKs; 8) 
encourage Dr Tesmer to resolve the structure of the GPCR-GRK complex. 
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APPENDIX 1 
Tables below (A-D) display ET results generated by Dr. Daniel Morgan from the Lichtarge 
group (Baylor College of Medicine) 
Top ranked residues of the RH and kinase domain are shown in red and yellow respectively. 
Table A. ET analysis of the RGS superfamily 
Alignment # Residue # Type Variability Rank Coverage
317 28 K KR.ASQDNTELHMP 62.66 0.7
318 29 K MK.RPHETAGCNQ 62.66 0.7
307 30 W CRWLIYES.DKTPFMGHANV 57.19 0.7
315 31 R RPQVLK.SETNDAWIGHMF 62.58 1.3
316 32 Q DPLERKHA.FSMQGYNTV 62.62 0.7
314 33 M ESNIPQMGK.LDVARFHTCW 62.44 0.7
294 34 L SENPLDK.VMRGQTYFCH 48.81 1.3
310 35 Q KETPNS.DGAQMVRHLIFY 59.68 0.7
308 36 F RSFKLM.VEATCIDGPHY 57.57 1.3
302 37 P PVMIAQ.GLSEKCDTYHNW 51.35 0.7
304 38 H PLDRHK.SGAEYNTVCFQ 53.65 0.7
309 39 I SNIVGA.LWPEKTCYFDRM 59.45 1.3
301 40 S NAP.SVETQRGCFKMLDI 51.11 0.7
306 41 Q LQT.MCPKSHNEAGDVRYW 55.77 0.7
287 42 C TDE.CQHPAKGRVILSYN 46.71 1.3
297 43 E LNK.SERDAHPCTQVWIYG 49.51 0.7
305 44 E ER.YDHNQSGVTKPAL 55.63 0.7
266 45 L EQV.LDPGCKYIHWARMTS 41.29 0.7
275 46 R VK.RELAPDGCQHMI 44.31 1.3
320 47 L LRKEHDA.SWQMTYVNPGIC 62.66 0.7
303 48 S QKRSTNDG.VAHWLIEM 52.34 0.7
264 49 L WIGHL.RNFMVDTAQS 40.49 1.3
291 50 E AEDVRKGS.TQP 48.21 0.7
300 51 R QTIFKVRLEG.DMAHSPC 50.99 0.7
222 52 D SNDTE.YGALRHQIV 32.56 1.3
155 53 Y FLIY.MSHAW 23.67 0.7
285 54 H ESYDVHN.TRCQGMPKA 45.82 0.7
263 55 S NSEKHLRF.VTDAPMIYGQ 40.28 0.7
168 56 L LSIVM.ANT 27.40 0.7
139 57 C MLVICFK.YHGA 20.87 0.7
295 58 E ADSRNQLGEKHV.TYI 49.14 0.7
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321 59 R .KEDQRS 62.66 0.7
158 60 N TDQNS.HCAEF 24.71 1.3
201 61 P KPRASDH.QNEVT 29.13 0.7
243 62 I YKTILVNA.CDESPRGM 34.12 1.3
1 63 G G.L 5.75 0.7
166 64 R PVLRYFKAM.IHQS 27.00 0.7
271 65 L VAQLRKNE.DISYTGMH 43.96 1.3
163 66 L VESLYTAQ.NHRMFCD 25.62 1.3
17 67 F YF.L 8.70 1.3
200 68 R AITQRKHSL.MG 29.08 0.7
250 69 E ADGYQELSR.IKTMHN 37.42 0.7
41 70 F YF.S 11.61 1.3
9 71 C LC.IYSA 8.36 0.7
235 72 A KEDLNRQPA.MGH 33.65 0.7
323 73 T .TNSVQDAK 62.66 0.7
245 74 R MKHRG.SEAVFLTQDCNY 34.82 0.7
141 75 P EPMSYFI.LDVGKNCTQA 21.45 0.7
249 76 E HFYTEGDLSNKVAP.RQ 37.18 0.7
144 77 L SLEVKHCQY.FND 21.68 1.3
252 78 S DEHGKIS.AVLQRTN 38.06 0.7
140 79 R ERPCLAGD.SKQVH 21.23 0.7
87 80 C NHLYECQAT.PV 15.78 0.7
212 81 V ILVM.STANCR 31.24 0.7
240 82 A QLRGENTKDYS.AH 33.85 0.7
2 83 F FL.IY 7.08 0.7
8 84 L WLYI.F 7.50 1.3
167 85 D MLIEDKQFTVG.N 27.27 0.7
136 86 G AELDV.SHGQT 19.54 0.7
22 87 V CVI.EAL 9.12 0.7
172 - . .V 62.66 0.7
135 88 A ENAKGQ.STV 18.22 0.7
214 89 E TDREKYGN.SALQ 31.71 1.3
52 90 Y YFLI.WMGH 13.84 1.3
47 91 E KREQDNHS. 12.35 0.7
234 92 V KRYVIGHQTLFAMWC. 33.03 0.7
230 93 T ITSGALMEQVRNC.D 32.93 0.7
258 94 P SDAPKHNTL.IEFGCQM 38.69 1.3
254 95 D RKHQDEPANLGTISYV. 38.51 1.3
280 96 D WDSELTKAIHRQPNVF. 45.78 1.3
267 97 K SQKDENALVTRGIMH. 41.94 1.3
203 98 R RMVLSQIKTW. 29.71 1.3
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299 99 K ILAKSTGHRPEVNQDFM. 49.60 0.7
288 100 A SKREDVAQTCYHPLMGIN. 46.94 1.3
171 101 C RKCQLYEMFTVAHNS. 28.82 1.3
45 102 G AVGSLIRM. 11.80 0.7
248 103 R KHNELRTQ.DSCFA 37.07 0.7
292 104 N KDESQRHTLA.IMNGVFY 48.40 0.7
34 105 L LIV.MA 11.20 0.7
160 106 T YLFMW.VITARHG 25.00 1.3
261 107 Q KTEDYNASQ.RMLVHG 39.67 0.7
257 108 N ITELRKQD.ASVWNMH 38.66 0.7
76 109 F YFH.CM 14.11 1.3
120 110 L ILF.AVMC 17.97 0.7
229 111 S QSKANMTRCDE.VLHW 32.83 0.7
324 112 H P.NKRVEADHTMS 62.66 0.7
236 113 T QSPKE.TINGVADMFR 33.82 0.7
219 114 G SKGLVEQANDRMH 32.32 1.3
142 115 P PALGKSEDTCMQ 21.46 0.7
244 116 D RSPAVKLTIQGCH.DNYE 34.50 1.3
255 117 L ETCRPFQSKVHDA.YLN 38.52 0.7
148 118 I IQEWLSCPAVTG 22.54 0.7
157 119 P .VIPHASKECRTNQYDG 24.47 0.7
137 120 E NELQDPFSTR.IAY 20.07 0.7
143 121 V IVFLYDT.M 21.62 0.7
70 122 P DEPSGTKLNF 13.93 0.7
159 123 R SGPKQHREDFAYWC 24.89 1.3
269 124 Q SQKDTHFREGACPVYNI 42.22 1.3
150 125 L T.VALESIGMRD 23.17 1.3
152 126 V R.MVTKLIQFYHNAP 23.42 0.7
251 127 T ESDTNKRWA.GVFHQI 37.67 0.7
274 128 N TKSIEHQNLVFARYGM.W 44.16 1.3
147 129 C IVTCGFL.KQAPM 22.41 0.7
262 130 T ISLVRQEWKANMCHTGP. 40.04 0.7
268 131 Q REKLSDTQWMHGNCAV 42.16 0.7
247 132 R NKGRAFVHDESPCYT 36.15 0.7
169 133 L IMLPVAHSTFC 27.92 0.7
276 134 E QLKTVASERGMPNFDIC 44.75 0.7
259 135 Q ENHKQGDASRTMICPV 38.82 0.7
325 136 G .ENQSRDAGKTILFV 62.66 0.7
145 137 P PVKALIGECSFHD. 21.77 0.7
256 138 C THSPCEDRQAGNVF.Y 38.57 1.3
277 139 K EPRKTSADQLIVNHFY. 44.90 0.7
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286 140 D TLFYKDESVGQHARNPCIW.M 46.03 1.3
162 141 L CMTVLISGAF. 25.25 0.7
23 142 F FLYVSAM. 9.63 0.7
199 143 Q EQDSNYRKAHTLGV.C 28.85 0.7
226 144 E EKSAPDLVQMTH. 32.78 0.7
97 145 L AHCYIQLTSKV.P 15.89 0.7
113 146 T QSTIAKLMVEG.R 17.77 0.7
241 147 R KDETRQS.WLGMAVHNCI 33.97 0.7
156 148 L IQHVESNR.KALTMW 24.23 0.7
165 149 T VIAL.TEPC 26.30 1.3
149 150 H YFMHCRL.QGVDK 22.96 1.3
289 151 E MNLQDRT.AEKSCGHYIV 47.15 0.7
146 152 Y HLYRKT.SAFNVMCDQ 22.13 0.7
7 153 L MLF.IR 7.30 0.7
138 154 S EKRNSGHQADT.L 20.51 0.7
206 155 V RYKGDEFQMSNAHTV. 30.77 1.3
153 156 A DEKSANTQVI.GH 23.64 0.7
81 157 P SCPVYIETA.L 15.63 1.3
25 158 F YFL.H 11.05 1.3
253 159 A PSAEQHGTN.RKV 38.12 0.7
127 160 D REKP.MFSLDVAQ 18.16 0.7
27 161 Y FY. 11.07 0.7
164 162 L LIQVM.K 26.19 0.7
170 163 D KREDLG.TNVSQA 28.55 0.7
11 164 S S.TA 8.65 1.3
290 165 I EPSMDLQ.NARTKIGYHF 47.66 0.7
227 166 Y MTHIYKRQAL.FVSE 32.81 0.7
102 167 F YF.QLC 17.54 1.3
246 168 N QLKSTD.RNMGHFEYA 35.80 0.7
260 169 R KRDQ.ECSNGATHVL 38.96 0.7
154 170 F LMFY.CHVI 23.66 0.7
202 171 L L.CAIVTSRMF 29.59 0.7
326 172 Q .AQRENPKMS 62.66 0.7
327 173 W .WTQAKRLSFG 62.66 0.7
329 174 K K.ASERGP 62.66 0.7
330 175 W TDAWN.LCVESRGKIQ 62.66 1.3
335 176 L MKTILV.AFSEYP 62.66 0.7
336 177 E QEG.VNSKFDCRMLA 62.66 0.7
270 178 R SEIPRL.TAVMKDGQHC 43.12 1.3
265 179 Q NQ.ETRSVGDKHIA 41.08 0.7
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278 180 P NEPIL.AGQSMRHYCTDK 44.98 0.7
 
 
 
Table B. ET analysis of the RH domain of the GRK subfamily 
Alignment # Residue # Type Variability Rank Coverage
1 28 K QKR.L 4.95 21.6
2 29 K RK. 4.19 17.0
3 30 W RYFHWLI.VP 7.68 40.5
4 31 R RHLKN.VP 9.37 50.3
5 32 Q RKASEQNLD 8 41.8
6 33 M SKRLIMYP 8.24 45.1
7 34 L LDEG 4.43 20.3
8 35 Q MASKRTQPH. 10.41 62.7
9 36 F LFSC 5.38 24.2
10 37 P PVI 2.97 9.2
11 38 H GKHPR 4.97 22.2
12 39 I PLIVYS 6.26 32.0
19 40 S QDETSNVI 6.95 34.6
20 41 Q SCGQVKME 7.79 41.2
21 42 C CYQH 3.94 15.7
22 43 E ETAGVSILKR 9.18 49.0
23 44 E QEAGSDNPYHF 12.56 79.1
24 45 L LV 1.66 1.3
25 46 R RKEALQ 6.16 29.4
26 47 L QESDAWHRLTK 13.14 85.0
27 48 S ASKTNREM 12.73 80.4
28 49 L MLIVGHN 10.93 66.7
65 50 E PASEDV 10.37 61.4
66 51 R ATQLPKRIVM 12.91 82.4
67 52 D DNHQGAESTK 10.12 58.2
68 53 Y FY 3.41 11.8
69 54 H NHETKQDRSGYCA 17.88 98.7
70 55 S SNLTGWYFKH 10.35 60.8
71 56 L LIVMQN 7.67 39.2
72 57 C CIVF 2.28 5.9
73 58 E EVSLDN 8.93 47.7
74 59 R QRKE. 18.44 100.0
75 60 N QNHE 3.35 10.5
76 61 P PAVKR 5.65 26.8
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77 62 I IVL 4.29 18.3
78 63 G G 1 0.7
79 64 R RKHYF 7.12 35.3
80 65 L RKLEMV 6.43 34.0
81 66 L LF 2.4 7.8
82 67 F FYL 2.34 6.5
83 68 R RQHK 5.35 23.5
84 69 E DQEL 6.16 29.4
85 70 F FY 3.86 15.0
86 71 C LCYSA 4.38 19.6
87 72 A AEDKQRNL 13.04 83.7
88 73 T TNQSAK 8.19 44.4
89 74 R VTGINDAHKRYE 14.95 90.2
90 75 P PGNQERSLMIC 10.23 59.5
91 76 E APTKERQGDSN 15.18 92.2
92 77 L YFNEHLVQDS 9.49 52.3
94 78 S QRSLKNHVGAETFIC 18.44 100.0
95 79 R EGKQVLAPRCSH 14.22 87.6
96 80 C APCHYQLE 8.96 48.4
97 81 V MRVACSLGIT 13.24 86.3
98 82 A GATDERQKN 12.91 82.4
99 83 F FL 1.88 2.6
100 84 L LWFY 3.59 12.4
101 85 D EDKT 4.37 19.0
102 86 G EDALSGKQ 10.27 60.1
103 87 V VLIA 4.48 20.9
131 88 A QSYNEAVK 7.36 36.6
132 89 E SNDTEAKL 11.67 71.2
133 90 Y WYF 3.8 13.7
134 91 E EDNQ 5.16 22.9
135 92 V LTMCVIKGA 10.51 64.1
172 93 T ASCTLIM 8.01 42.5
174 94 P EDIPTCSNK 10.13 58.8
175 95 D GDANEQYKP 9.32 49.7
176 96 D PNAKESDG 9.62 52.9
177 97 K AVTIDELKNG 12.55 78.4
178 98 R KRQL 6.34 32.7
179 99 K GDTSAPRKLVI 15.32 93.5
195 100 A SKQAEDHRVCT 13.94 86.9
196 101 C TAMKFCHRVQ 12.94 83.0
199 102 G LMRAGNS 6.14 28.1
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200 103 R QETASLKRCNF 11.23 68.0
201 104 N AGQNKTSRED 15.11 91.5
202 105 L LITVM 6.26 32.0
203 106 T VAILRFYMT 12.81 81.0
204 107 Q ATNQSKD 9.84 54.9
205 108 N TNKREQAILSH 15.76 96.7
206 109 F CFYLH 7.38 37.3
221 110 L AVLCMFIH 7.65 38.6
222 111 S VASRKEDTNM 12.26 76.5
223 112 H ADTPENHKRV 11.87 73.2
234 113 T PGDSQKNTE 9.85 55.6
235 114 G NVAGSLKQM 11.3 69.9
236 115 P PKTQAEL 8.18 43.8
294 116 D GQNTSHLEVADF 11.92 73.9
295 117 L QRHN.YFSPLVWC 16.69 98.0
296 118 I P.LCITSA 8.89 47.1
297 119 P HQSTPNADY 11.25 69.3
298 120 E SPFEQVLADN 12.57 79.7
299 121 V FLMIVY 8.12 43.1
300 122 P LFSTPDGN 10.4 62.1
301 123 R SQGREAPDK 10.78 65.4
302 124 Q PQDENGAHST 15.55 95.4
303 125 L ALPVDGIMTS 13.23 85.6
304 126 V LVAIT 10.05 57.5
305 127 T VATSEKHQN 15.58 96.1
306 128 N TKRPEQNSHF 10.81 66.0
307 129 C KCVFAPT 7.68 40.5
312 130 T CRQKAESTD 10.54 64.7
313 131 Q QASEDWCLKNGY 15 90.8
316 132 R ADVRKNGSYH 12.13 75.2
317 133 L ATSHLPG 8.32 46.4
318 134 E TEDKVGALNHS 15.43 94.8
319 135 Q TDKFEVGPQS 10 56.9
321 136 G ED.SNKGQR 11.25 69.3
322 137 P EDVASI.PGK 10.46 63.4
323 138 C RQYMFAG.SCPT 12.11 74.5
324 139 K ARVKED.QSPT 14.82 89.5
325 140 D SVATNEDGKQ 14.41 88.2
326 141 L LAVKDI 6.43 34.0
331 142 F VMF 2.79 8.5
332 143 Q EATQGVSKNH 14.44 88.9
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333 144 E QLDEAPKR 12.5 77.1
334 145 L AGVITLCPY 8.32 46.4
335 146 T KRVQMLATSYI 13.14 85.0
336 147 R ADREQGNL 11.78 72.5
337 148 L E.ASKIVL 9.43 51.6
338 149 T AVT.LI 12.24 75.8
339 150 H MK.FLCYHR 11.72 71.9
340 151 E ATSVEDKNQR 15.4 94.1
341 152 Y FYHQNRSK 9.4 51.0
342 153 L LF 1.75 2.0
343 154 S QKRSGETAN 12.52 77.8
344 155 V DEGQMVTK 11.02 67.3
345 156 A QKVAGTEIDNS 15.96 97.4
346 157 P PAVILE 6.25 30.7
347 158 F FYWL 4.18 16.3
348 159 A RQKTVAEGHNS 15.25 92.8
349 160 D EDFPKR 7.57 37.9
350 161 Y FY 5.4 24.8
351 162 L LVQEAIM 9.75 53.6
352 163 D VATGEDS 9.82 54.2
353 164 S ST. 3.22 9.8
354 165 I PAQEMLTSID. 11.49 70.6
355 166 Y FYK.R 6.08 27.5
356 167 F YFL. 7.3 35.9
357 168 N DEKLGNSHT. 9.98 56.2
358 169 R KRQ. 4.29 18.3
359 170 F FY. 3.37 11.1
360 171 L LTC. 3.8 13.7
361 172 Q Q. 2.01 4.6
362 173 W WF. 2.39 7.2
363 174 K K. 2.01 4.6
364 175 W VLEWN. 5.54 26.1
365 176 L FYLV. 5.43 25.5
366 177 E E. 2.01 4.6
367 178 R MKAGRL. 6.17 30.1
368 179 Q QRN 3.81 14.4
369 180 P PIM 2.19 5.2
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Table C. ET analysis of the AGC kinases superfamily 
Alignment # Residue # Type Variability Rank Coverage
6 180 P KSRNQP.GVTYIELHDMAF 62.06 84.6
7 181 V YITWEL.HFMASVCKPNR 50.07 75.2
8 182 T SVTAGKQRH.NCEPFD 63.19 85.5
9 183 K LYIP.VSFMTAKQRDE 35.77 57.6
10 184 N QKSYNHTGDAI.RELP 66.59 88.1
11 185 T DNFE.QHVASCRTYW 37.77 61.1
12 186 F FLP.YWV 11.79 18.3
13 187 R QSDETALNHK.IRVYM 64.55 86.8
14 188 Q ILVFMQ.TRKHGYPEACD 42.38 68.5
15 189 Y LMQERKGYVIH.CF 41.01 67.2
16 190 R RQNDE.KAICTSGMVHY 34.34 55.6
17 191 V TSVNILKM. 19.64 34.1
18 192 L LVRIS. 17.39 30.5
19 193 G G.D 1.9 2.6
20 194 K T.KSMNREVIGQA 24.31 41.8
21 195 G GHDC 2.9 5.5
22 196 G STPLAQGNHM 15.81 28.0
23 197 F FLMYV 8.18 12.5
24 198 G GSALR 3.72 6.8
25 199 E RPKTIVNQE 12.47 19.3
26 200 V VSAGI 3.93 7.4
27 201 C HRPLYCNEWIMQKTSFV 32.43 52.4
28 202 A LISFQMVKEGA 14.28 23.5
29 203 C IVTACSRG 20.01 35.0
30 204 Q RQHKLTDECVPIMS 39.26 63.3
31 205 V SLRHQNDEPFYTIVA.KMG 85.07 100.0
32 206 R RNIVKTASMHQGELFYD 56.58 81.4
33 207 A HSGDK.NRQIVEATMFL 37.14 59.2
34 208 T .RPEDASLGTKNHQV 33.95 55.0
35 209 G .DAQTESKRNCGPIHV 34.29 55.3
36 210 K .VENIQKSRDGATLPF 85.07 100.0
47 211 M .PVIFYLWTM 22.64 38.6
48 212 Y .MVYFSLC 13.71 21.9
49 213 A ASVT 3.37 5.8
50 214 C MLIVHASQCN 25.39 43.4
51 215 K KR 1.28 1.3
52 216 K VTCIKRMQASYLE 29.15 47.6
53 217 L LMFYVI 14.69 23.8
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54 218 E KNREASDPQHGTC 29.57 47.9
55 219 K KMIWRF 5.06 8.7
56 220 K EHQAKRSTPVCFLDIGN 37.67 60.8
58 221 R ITVRQKEDYSNHALMF 39.96 64.6
59 222 I VILMF 21.7 37.9
60 223 K VILRKMNHTFQAS 33.19 53.7
61 224 K RKQDSYANELIMGTC.V 40.54 65.9
88 225 R LMHQTNCKRDEF.AVS 28.23 45.7
89 226 K KRNSQPCDEHGT 24.5 42.4
90 227 G QMTL.EDAHSGNR 13.36 20.6
91 228 E VIQEGTL.MARSYF 30.6 49.2
92 229 A EQDSANRKTVM 38.1 61.7
93 230 M HNCASLWYRQTMG 16.52 29.3
94 231 A TVILMAPS 18.09 32.2
95 232 L NCLASMKQHRFTYIVE 38.28 62.4
96 233 N DSNQAHLCGTIVME 32.6 52.7
97 234 E EVK 2.26 3.5
98 235 K RKACQSNHIL 15.91 28.6
99 236 Q LRKSEAYGQICNHTDV 46.96 73.6
100 237 I MILVAF 13.78 22.2
101 238 L LMTQF 10.05 14.8
102 239 E SKGQNVEMTRLAIY 41.7 67.8
103 240 K IVLEDRQSKAYGNT.CH 50.72 76.8
104 241 V VAILMNTSC.QPRGEF 36.11 58.2
105 242 N TSQEKRDCHNAGVFWP.LY 52.14 77.5
106 243 S .GNSATMLKERHQDIC 85.07 100.0
107 244 R .PKADLGVMITENRQ 85.07 100.0
116 245 F FNWSY.L 7.85 12.2
117 246 V ILVCT.M 20.28 35.7
118 247 V IVTMC.LA 18.05 31.8
119 248 S RTNIASEKGYCPQLH.D 46.17 73.3
120 249 L MLCQFV. 12.93 19.6
121 250 A WHMLIYREFTQKADVNC.S 43.09 69.8
122 251 Y GSCKRAQWTFYNDI.VH 27.14 44.4
123 252 A TSGANHC. 23.63 41.2
124 253 Y FWYSTGEL.ID 15.51 26.7
125 254 E QKMHWASRTE.FD 19.53 33.8
126 255 T DECSTNAF.H 12.16 18.6
127 256 K ASCWVEDKQNHTFRPMG. 56.35 81.0
128 257 D QHRKNTAICSYDEMG. 47.97 74.3
129 258 A QNFKRCHSYDEP.A 32.92 53.4
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130 259 L IVLCFA. 14.72 24.1
131 260 C FYCVR.HIGS 14.78 24.8
132 261 L MIFL. 17.43 31.2
133 262 V IVLMFCA.S 19.69 34.4
134 263 L MILFTV. 15.71 27.3
135 264 T DLEFSRPAQ.T 19.72 34.7
136 265 L YKFLAVSTHC.I 28.26 46.0
137 266 M IVALCRMKS.F 31.31 49.8
138 267 N EAPTMVNSCILQGKRH. 32.26 51.8
139 268 G GR. 2.52 4.8
140 269 G G.KM 4.36 7.7
141 270 D E.DHQ 8.35 12.9
142 271 L LMIVFS. 15.08 26.0
143 272 K FYWMSILH.KR 14 23.2
144 273 F STHYDFWILMRAV. 36.07 57.9
145 274 H LYHFRAVITMQ.W 17.23 30.2
146 275 I LHICVMA. 12.19 19.0
147 276 Y RQVKDSNLHYAE.CG 17.86 31.5
148 277 H KRTSNAHEDGL.QPM 39.26 63.7
149 278 M SCARYNIVKLE.DQTMFH 35.65 57.2
150 279 G QKGHMNRVDATE.LS 85.07 100.0
174 280 Q .LEDCKQNPT 85.07 100.0
175 281 A .QGRKEHDNIAP 85.07 100.0
176 282 G RDKHCSTLNQYFGEVIMAP. 40.63 66.2
177 283 F FILMSW. 9.38 13.8
178 284 P PSDTNAGQELKRM. 55.99 80.4
179 285 E NTHEASLRKDMVQP 21.11 37.3
180 286 A PSKNDAQVTYLGREH 64.38 86.5
181 287 R VTQAMHNWELRPDYI 28.18 45.3
182 288 A ASTGCVLMI 27.31 44.7
183 289 V KQRNVLCTAGIMS 37.22 59.5
184 290 F FILYAVSH 14.77 24.4
185 291 Y YFCIV 5.2 9.0
186 292 A AHCLISGTVPM 32.3 52.1
189 293 A ASCTVG 19.11 33.4
190 294 E ESTQCN 11.25 16.7
191 295 I VALIMNT 23.14 40.8
192 296 C CFITAVLHRSM 44.38 70.1
193 297 C LSCMNEQTVIAF 31.36 50.2
194 298 G AIVTSCGR 18.57 32.5
195 299 L LIFVPTM 18.84 32.8
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196 300 E EDQGASHRIKLFMVN 34.58 56.3
197 301 D YFKNTSCVHAQD 23.12 40.2
198 302 L LIMSQFV 9.81 14.1
199 303 H HQNR 5.03 8.4
200 304 R SAKTQHNEDYMGRL.V 49.11 74.9
204 305 E KLHRQNMEDCFYISG 54.21 78.8
205 306 R DNQTKHSEG.RFYC 40.07 65.3
206 307 I IVLMT 20.62 36.0
207 308 V ITVLAM 28.45 46.3
208 309 Y YHLFI 2.84 5.1
209 310 R RK 2.44 4.2
210 311 D DKN 1.44 1.9
211 312 L LMFVIC 13.29 20.3
212 313 K KC 1.31 1.6
214 314 P PL 3.73 7.1
215 315 E EDNA 6.21 10.9
216 316 N NSD 2.25 3.2
217 317 I ILVFCT 16.55 29.6
218 318 L LMIF.V 14.8 25.4
219 319 L LIMV. 11.34 17.0
220 320 D DGSNQMATEC 15.85 28.3
227 321 D .EDSN 85.07 100.0
228 322 H .HFYNSRLQEDA 85.07 100.0
229 323 G GA 1.76 2.3
230 324 H HNYFSQ 14.79 25.1
231 325 I ILVTMCAGS 37.27 59.8
232 326 R KRAQYVICEML 13.87 22.8
233 327 I ILVMQ 20.95 36.7
234 328 S TVAIGCS 10.83 16.1
235 329 D DN 2.2 2.9
236 330 L FLMY 5.73 10.0
237 331 G G 1 0.3
238 332 L FCTLMV 6.16 10.6
239 333 A ADTCSR 10.62 15.8
240 334 V KRVCLMTI 7.79 11.9
241 335 H .PLAEKQDTMYIVRH 20.87 36.3
242 336 V .VLGDQENHSFACIMK 85.07 100.0
243 337 P YERKHVQIL.FNDGCMSAPT 45.59 72.3
244 338 E VLI.KMSTFWYNCARGDQEP 45.31 72.0
245 339 G PQDSTEKRVIGNAYFLHCM 52.05 77.2
246 340 Q .TDNGEMVIRKFSHAYPQL 52.77 78.1
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258 341 T VKINR.EHLATGQMCSP 36.81 58.5
259 342 I TCASMP.NLGIV 22.93 39.5
260 343 K YWCFSMDNRTQGKAHLV 35.13 56.9
261 344 G TSPAGQE 7 11.6
262 345 R LIMFYQ.SRKT 13.66 21.5
263 346 V CVAIT.S 8.97 13.5
264 347 G GI. 1.17 1.0
265 348 T TS. 1.17 1.0
266 349 V PHTSLIVEQ.NG 16.72 29.9
267 350 G DEQHGNSA 10.07 15.1
268 351 Y Y.F 5.71 9.6
269 352 M ILTMV.SCF 13.87 22.8
270 353 A APS.D 6.65 11.3
271 354 P P.G 2.47 4.5
272 355 E EK.GD 4.46 8.0
273 356 V VISMNL.TFQK 20.22 35.4
274 357 V VIL.P 85.07 100.0
275 358 K SATQLGHRKM.NIVCEDF 48.65 74.6
277 359 N .GNDEKARLQSCMTH 85.07 100.0
278 360 E TNSLCRAG.EDYQKPH 30.7 49.5
279 361 R KRQSTVAHLC.ENIMDP 52.68 77.8
281 362 Y YH.QCD 5.83 10.3
282 363 T NGDTAS.R 38.11 62.1
283 364 F KRSLTMCFIHQYN.PAGVE 41.08 67.5
284 365 S SAPGQTVMH.ECND 32.21 51.4
285 366 P IVAWCT.SP 21.06 37.0
286 367 D DT. 3.64 6.4
287 368 W WTIALYF.MVC 15.6 27.0
289 369 W WYSG.RF 10.35 15.4
290 370 A SATGC. 23.14 40.8
291 371 L FLMYI.TVA 29.13 47.3
292 372 G G. 3.5 6.1
293 373 C IVTA.SC 24.38 42.1
294 374 L LFCYV.MIST 15.38 26.4
295 375 L ILTGVFM.CA 31.67 50.5
296 376 Y YFCH. 24.63 42.8
297 377 E EV.RQDK 9.93 14.5
298 378 M MFIL. 13.45 21.2
299 379 I LIFMANVCT. 27.72 45.0
300 380 A ATCVGSINLY.HFEMRKQD 34.36 55.9
301 381 G GRD.CQA 11.16 16.4
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302 382 Q YFHLKIQCRSPEGTNW.VAD 44.79 70.7
303 383 S TPSAVLQ.CGR 24.8 43.1
304 384 P P. 5.6 9.3
305 385 F .PF 85.07 100.0
306 386 Q .PFRQK 85.07 100.0
310 387 Q .QGKAMDSTVR 85.07 100.0
311 388 R FIAVYL.QRK 16.2 28.9
312 389 K YWFVRDHNGASTQEP.KLI 37.95 61.4
313 390 K DNTSGHA.CILVYKE 29.8 48.6
314 391 K SQPTVNEDKR.CIAG 40.97 66.9
315 392 I .GDQVNEKYTHSRI 85.07 100.0
316 393 K .AEQLTDSGKN 85.07 100.0
325 394 R TPHLVQINED.SRKAW 29.13 47.3
326 395 E MILVFSDYPNQAEGT.CKRH 39.96 65.0
327 396 E KGRLAEQSVMITDYF. 37.47 60.1
328 397 V TILMV.K 23.9 41.5
329 398 E YFCEM.VIDSAQLKTR 22.72 39.2
330 399 R EQNRDKSTAMHW. 42.44 68.8
331 400 L KNAQLRDEISV.CTM 31.73 50.8
332 401 V IVT.M 11.68 18.0
333 402 K LIVCMATQRK.EP 33.56 54.0
334 403 E NQAKRESVLTYIGDFHM. 56.22 80.7
335 404 V AGCHK.EQNDSRMTIV 45.03 71.1
336 405 P .IVNAPETQS 85.07 100.0
337 406 E .GSTDEYVP 85.07 100.0
338 407 E ESKRDNPIQMHAVT. 42.97 69.5
339 408 Y LVIFPYMA.KQW 29.75 48.2
340 409 S RKTVHNQLAEDSYIMFPW.G 50.28 75.9
341 410 E FYWMIL.CVPADESHT 34.71 56.6
342 411 R PSETAKRL.GVQD 21.44 37.6
354 412 F FLIVMTNKDER.W 33.88 54.7
355 413 S NHPQDESGTKA.LF 40.89 66.6
356 414 P EPATVGSYFLNKQRD. 73.96 91.0
357 415 Q DKLGARFYITHNEQSWP.V 50.49 76.2
358 416 A VAISCLTPG.M 32.77 53.1
359 417 R KQRLVICGAHSTEWM. 47.41 74.0
360 418 S DNESHKVAQTGR.LC 42.29 68.2
361 419 L LMFIVAC.Y 31.75 51.1
362 420 C LIVMC.FA 25.44 43.7
363 421 S SKQGTERDHIMAV.LNC 42.82 69.1
364 422 Q RKQNHGSCELPAVWM 45.07 71.4
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365 423 L LFICVM 13.45 21.2
366 424 L ILCQMFP 14.84 25.7
367 425 C TVIQSEKNCRHMADG 45.99 73.0
368 426 K RKADSGTLHNVPQE 23.12 40.2
369 427 D DNLVTQKAEHCSR 39.81 64.3
370 428 P LIHPRVTKAQYSE. 28.92 46.6
371 429 A STLEQCMAGKNRDVHFIYP. 68.06 89.1
372 430 E QEKRCHVGLTNDMIAS.F 50.11 75.6
373 431 R R.S 2.33 3.9
374 432 L LIY.FKMWP 17.42 30.9
375 433 G G.LAKQTNDM 8.78 13.2
376 434 C NT.ACHEGYSMVFDL 39.36 64.0
377 435 R .SVITQHKRGLNDACYMP 85.07 100.0
378 436 G L.MQISRGNDAEKPTVH 55.63 79.7
379 437 G .TSAPYFEDRGKNV 85.07 100.0
401 438 S G.QREDAIKNST 85.07 100.0
402 439 A TSPA.VRNCYFIGELM 85.07 100.0
403 440 R EQDRANSKM.TLGVPHIC 71.66 90.7
404 441 E DG.RNSEALQTMPKCV 37.04 58.8
405 442 V VI.ELPMFY 33.83 54.3
406 443 K KRFI.MSQVCLNAT 37.56 60.5
407 444 E NASTGM.KRHDELQVIYC 79.13 91.3
408 445 H H.QVNMARELSD 22.37 38.3
409 446 P PQGLK.RVEAIMSFDTCNH 57.96 83.0
410 447 L WY.FRPLGIV 18.94 33.1
411 448 F F.GLYSW 11.56 17.4
412 449 K KNSQARH.YETGDMLVC 69.44 89.7
413 450 K EDG.HSKNTRQALPYFW 57.48 82.3
423 451 L VILA.TFMW 38.82 63.0
424 452 N VITDSNEQYHA.GKP 44.4 70.4
425 453 F WFC. 11.64 17.7
426 454 K EDTNRKVIFHYSLWQA.GP 67.81 88.7
427 455 R KRMVSADNGPWELQH.TY 60.65 83.9
428 456 L LIVCTQF.AMPW 26.19 44.1
429 457 G LAYFEQIPRKMWCTGSNVD. 57.5 82.6
430 458 A SACRKTNEQHYPMGDL.I 64.75 87.1
431 459 G RKGLMQSFC.NAVWH 38.46 62.7
432 460 M NYDEKQRAHTVSGL.MIP 62.38 84.9
433 461 L .WYLNVIP 85.07 100.0
434 462 E IYDLVFMERG.ATHPQ 60.16 83.6
435 463 P EDPGLNRKTSVMIQA.H 67.76 88.4
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436 464 P TAVPGSLH.RQKI 22.71 38.9
437 465 F PL.TAHSEFW 13.11 19.9
438 466 K YIFS.WALRGTVKC 30.58 48.9
439 467 P ETVLPIKF.QHAYMRNC 54.75 79.4
440 468 D PVS.HRLIGDK 15.73 27.7
441 469 P PKTRYND.FSAEIHQVMCLG 58.25 83.3
442 470 Q IVNAQLTYCG.FRSPEMHK 53.66 78.5
443 471 A QHTKRDAGVSYE.NLMCIF 71.12 90.4
444 472 I QASGE.FHYNRDTKPVI 50.63 76.5
445 473 Y GASTKRHDPNI.VMELQCY 54.24 79.1
446 474 C QVIATSEDMPGF.YLNRKHC 61.72 84.2
474 492 E GSPVQRKAIED.YHTNMWCL 68.86 89.4
475 493 P VIAS.GKRPTLHYEDNMF 65.69 87.5
476 494 T QLSIMVTCAYF.NHKEWPGD 56.99 81.7
477 495 D GSTQADFYPNEV.CKIMLHR 40.12 65.6
478 496 Q .VGNLEDFYASIRCPTQK 45.14 71.7
479 497 D .YGRSMLVDKQCEHTAIPFN 85.07 100.0
480 498 F EDHSP.VAYNKFITRQML 85.07 100.0
481 499 Y DGPSAKQE.VRNCYLTIF 45.78 72.7
482 500 Q PQEVSATIRKHD.LNGWFY 70.11 90.0
483 501 K YHLFQTDEMC.AGPWSNVKRI 64.35 86.2
484 502 F AMQRGDTYSLKNV.PEIFH 66.1 87.8
485 503 A DAESHNQGK.RLYFMPIVT 62.61 85.2
486 504 T LQYMFIECT.KPRVAGNSDH 63.69 85.9
487 505 G FMLSHWYP.VNTAQEDGICKR 57.39 82.0
488 506 S RKSQVLTPENIAHDYF.CGM 85.07 100.0
489 507 V DEGNHA.RSKVTLPMCQIFY 55.98 80.1
 
Table D. ET analysis of the kinase domain of the GRK subfamily 
Alignment # Residue # Type Variability Rank Coverage
1 180 P QNHTP 4.52 63.7
2 181 V LVIM 5.37 71.7
3 182 T TSDAG 5.92 75.2
4 183 K MKYDEA 4.88 68.2
5 184 N NKHD 2.96 46.0
6 185 T DETYWA 4.25 62.1
7 186 F F 1 19.0
8 187 R SRETYLA 5.12 69.5
9 188 Q VQHMLED 4.55 64.6
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10 189 Y HYF 2.61 40.2
11 190 R R 1 19.0
12 191 V IVT 2.22 34.4
13 192 L IL 1.69 27.7
14 193 G G 1 19.0
15 194 K RK 2.68 41.5
16 195 G G 1 19.0
17 196 G G 1 19.0
18 197 F F 1 19.0
19 198 G G 1 19.0
20 199 E EK 1.6 21.2
21 200 V V 1 19.0
22 201 C YCSF 3.59 53.4
23 202 A GA 1.69 27.7
24 203 C CV 1.82 29.6
25 204 Q RQ 1.69 27.7
26 205 V KVMR 2.77 43.1
27 206 R ARK 6.15 76.8
28 207 A DAN 2.43 37.3
29 208 T TS 1.34 19.6
30 209 G G 1 19.0
31 210 K KQ 1.56 20.3
32 211 M ML 2.74 42.8
33 212 Y Y 1 19.0
34 213 A A 1 19.0
35 214 C MCLN 2.61 40.2
36 215 K K 1 19.0
37 216 K CKR 3 47.3
38 217 L L 1 19.0
39 218 E DEQCN 4.04 57.9
40 219 K K 1 19.0
41 220 K K 1 19.0
42 221 R R 1 19.0
43 222 I IVL 3.45 52.1
44 223 K K 1 19.0
45 224 K MLK 2.68 41.5
46 225 R KR 3.23 49.5
47 226 K QGTKHNS 8.24 90.0
48 227 G GA 1.34 19.6
49 228 E EY 1.63 22.5
50 229 A MTASKEQ 6.22 77.5
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51 230 M LMGA 3.01 47.6
52 231 A AVS 1.76 28.9
53 232 L LMI 2.8 43.4
54 233 N NILSV 4.1 59.2
55 234 E E 1 19.0
56 235 K RK 1.69 27.7
57 236 Q NIQREK 7.06 82.6
58 237 I MI 1.69 27.7
59 238 L L 1 19.0
60 239 E QSEATM 5.59 73.0
61 240 K ALKR 5.27 71.1
62 241 V VLI 2.69 41.8
63 242 N SNHQ 4.94 68.8
64 243 S TS 1.69 27.7
65 244 R GVRQPL 5.66 73.3
70 245 F F 1 19.0
71 246 V IVL 5.83 74.6
72 247 V V 1 19.0
73 248 S CSN 4.17 60.8
74 249 L ML 1.69 27.7
75 250 A TSA 3.7 54.3
76 251 Y YC 1.6 21.2
77 252 A AT 2.06 29.9
78 253 Y FY 2.3 35.7
79 254 E HQRED 5.19 70.4
80 255 T TS 3.04 47.9
81 256 K PK 1.69 27.7
82 257 D DESTA 5.8 74.3
83 258 A KNAHED 4.72 65.6
84 259 L L 1 19.0
85 260 C CS 3.23 49.5
86 261 L FL 1.69 27.7
87 262 V ISV 2.47 38.3
88 263 L LM 2.09 31.5
89 264 T DTS 3.37 51.4
90 265 L LI 3.27 50.2
91 266 M M 1 19.0
92 267 N N 1 19.0
93 268 G G 1 19.0
94 269 G G 1 19.0
95 270 D D 1 19.0
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96 271 L LMVI 4.43 63.0
97 272 K HKR 2.24 35.4
98 273 F YF 2.96 46.0
99 274 H H 1 19.0
100 275 I LIV 2.52 39.2
101 276 Y SY 1.69 27.7
102 277 H QHNS 4.55 64.6
103 278 M HMLVI 4.09 58.8
104 279 G GMDN 3.14 48.9
111 280 Q .QNDEPT 13.02 100.0
112 281 A .APGRK 13.02 100.0
113 282 G IVG 2.44 37.9
114 283 F FLI 2.18 32.8
115 284 P SNPEDAQ 9.31 92.0
116 285 E ELM 2.23 34.7
117 286 A DQASKPEN 12.96 97.7
118 287 R EDR 3.79 55.9
119 288 A MVAI 3.89 56.3
120 289 V KRVLQIC 8.41 90.4
121 290 F FYSH 5.76 74.0
122 291 Y Y 1 19.0
123 292 A AST 4.18 61.1
124 293 A ATS 3.12 48.2
125 294 E EQ 2.09 31.5
126 295 I VILM 5.85 74.9
127 296 C ICLATV 6.77 79.4
128 297 C LCTQS 5.2 70.7
129 298 G G 1 19.0
130 299 L LVMI 4.16 60.5
131 300 E EQL 2.44 37.9
132 301 D HDQ 3.62 53.7
133 302 L MVL 2.48 38.6
134 303 H HQ 2.15 31.8
135 304 R KVNSTRHEGDQ 11.41 96.8
136 305 E RCEKQLMH 7.05 82.0
137 306 R CGFYRND 7.3 84.6
138 307 I IVT 4.33 62.7
139 308 V VLI 4.12 59.5
140 309 Y Y 1 19.0
141 310 R R 1 19.0
142 311 D D 1 19.0
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143 312 L LCM 3.43 51.8
144 313 K K 1 19.0
145 314 P P 1 19.0
146 315 E AE 1.69 27.7
147 316 N ND 2.17 32.5
148 317 I IV 2.09 31.5
149 318 L L 1 19.0
150 319 L L 1 19.0
151 320 D D 1 19.0
152 321 D EDSN 3.73 54.7
153 322 H NSHFYRLQEDA 10.03 93.9
154 323 G G 1 19.0
155 324 H HNQ 3.36 51.1
156 325 I IVAC 5.47 72.3
157 326 R R 1 19.0
158 327 I IL 2.31 36.0
159 328 S S 1 19.0
160 329 D D 1 19.0
161 330 L LM 1.6 21.2
162 331 G G 1 19.0
163 332 L L 1 19.0
164 333 A AT 2.21 33.8
165 334 V CVLMTI 5.37 71.7
166 335 H DHEKQ 5.54 72.7
167 336 V FVIML 6.23 77.8
168 337 P SPKQAL 7.32 84.9
169 338 E KEDGPVA 7.28 83.9
170 339 G KGND 4.24 61.4
171 340 Q KRQED 5.98 75.6
173 341 T .TMRLPIVK 13.02 100.0
174 342 I PIVT 4.85 67.8
175 343 K HKRQ 4.25 62.1
176 344 G AG. 2.43 37.3
177 345 R SRMKY 3.78 55.6
178 346 V VA 2.09 31.5
179 347 G G 1 19.0
180 348 T T 1 19.0
181 349 V HVNGP 3.28 50.5
182 350 G GA 1.56 20.3
183 351 Y YF 1.63 22.5
184 352 M M 1 19.0
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185 353 A AD 2.17 32.5
186 354 P P 1 19.0
187 355 E E 1 19.0
188 356 V VIL 3.65 54.0
189 357 V LVI 3.74 55.3
190 358 K SAQKRNDMTL 13.02 100.0
191 359 N KNHEDG 6.45 78.5
192 360 E GEQKT 4.03 57.6
193 361 R TVRKAPE 7.27 83.6
195 362 Y Y 1 19.0
196 363 T DTGASR 4.62 65.3
197 364 F SFLYTM 5.67 73.6
198 365 S CSGPA 4.77 66.2
199 366 P APV 2.73 42.1
200 367 D D 1 19.0
201 368 W WCY 3.55 52.4
202 369 W FW 2.49 38.9
203 370 A SAGT 4.8 66.6
204 371 L FLVM 4.09 58.8
205 372 G G 1 19.0
206 373 C CV 1.63 22.5
207 374 L MLFST 4.15 60.1
208 375 L LI 2.83 43.7
209 376 Y YF 2.89 44.4
210 377 E KE 1.69 27.7
211 378 M LMF 2.89 44.4
212 379 I LIV 3.89 56.6
213 380 A KRAQED 6.19 77.2
214 381 G GA 1.63 22.5
215 382 Q HQKRY 5.19 70.4
216 383 S SATG 3 47.3
217 384 P P 1 19.0
218 385 F F 1 19.0
219 386 Q RQK 4.96 69.1
223 387 Q .QKGMDSATR 13.02 100.0
224 388 R QRYFK 4.55 64.6
225 389 K HKG 2.24 35.4
226 390 K KE 2.74 42.8
227 391 K TK 1.69 27.7
228 392 I KRIV 4.73 65.9
229 393 K DKNSE 4.09 58.8
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230 394 R KRWN 4 56.9
231 395 E LHEK 2.99 46.3
232 396 E EDV 3.14 48.9
233 397 V IVML 5.16 69.8
234 398 E DEKQT 4.83 67.5
235 399 R KRQEH 7.1 83.0
236 400 L MLR 3 47.3
237 401 V TVI 4.92 68.5
238 402 K LMKRI 7.66 87.1
239 403 E TENKQSH 8.03 89.1
240 404 V MVEDTQ 9.54 92.6
241 405 P NAPTEQS 9.02 91.3
242 406 E VEP 2.63 40.8
243 407 E EQVKRATS 8.78 90.7
244 408 Y LYFW 3.59 53.4
245 409 S PTSQHE 6.07 76.5
246 410 E EDSPH 8.96 91.0
247 411 R STVARKQDE 11.21 96.5
249 412 F FM 2.07 30.2
250 413 S STND 4.51 63.3
251 414 P LTVPQSEDA 9.9 93.2
252 415 Q EQNDAPK 7.45 85.9
253 416 A LMATGS 6.47 78.8
254 417 R KRHI 7.57 86.2
255 418 S NSGTD 4.57 65.0
256 419 L LIMVF 6.93 81.4
257 420 C LCI 2.22 34.4
258 421 S ESRNKQ 7.25 83.3
259 422 Q MGQLA 6.86 80.7
260 423 L LF 1.82 29.6
261 424 L LP 2.21 33.8
262 425 C QKHNSCTIAE 11.9 97.1
263 426 K RK 1.69 27.7
264 427 D DENSTK 7.06 82.6
265 428 P VPSAI 6.89 81.0
266 429 A SENADKGQ 9.96 93.6
267 430 E KERQF 7.67 87.5
268 431 R RS 1.68 22.8
269 432 L L 1 19.0
270 433 G G 1 19.0
271 434 C CSMF 3.58 52.7
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272 435 R MKGLHYRQ 10.8 96.1
273 436 G GSREND 7.6 86.5
274 437 G NKRGDEV. 10.43 94.5
280 438 S .GS 13.02 100.0
281 439 A ASVGM.C 6.81 80.1
282 440 R DKEQSRA 10.71 95.5
283 441 E EAGDKM 6.97 81.7
284 442 V VLIP 5.44 72.0
285 443 K KMR 2.62 40.5
286 444 E METQRAKS 8.16 89.4
287 445 H HNSDQ 6.52 79.1
288 446 P NEDPVSIH 9.36 92.3
289 447 L FLIVW 6.03 76.2
290 448 F F 1 19.0
291 449 K CKRGHNQS 9.62 92.9
292 450 K GDSAKNTEQ 10.76 95.8
302 451 L IMLV 10.04 94.2
303 452 N DNPSH 4.13 59.8
304 453 F WF 2.32 36.3
305 454 K HNQKSRPAG 7.9 88.4
306 455 R QMHYRKS 7.69 87.8
307 456 L VLMW 2.61 40.2
308 457 G YFLGEDNS 8.17 89.7
309 458 A IQLA. 4.01 57.2
310 459 G QLRGN 4.82 67.2
311 460 M KRHMLIP 6.83 80.4
312 461 L Y.LVIP 6.01 75.9
313 462 E TP.QEDIM 10.6 94.9
314 463 P P. 1.7 28.6
315 464 P P. 1.7 28.6
316 465 F L.FW 2.91 45.3
317 466 K VI.KC 7.42 85.5
318 467 P P. 1.7 28.6
319 468 D P.DK 2.91 45.3
320 469 P R.PS 3.3 50.8
321 470 Q GQEHRSNK 7.7 88.1
322 471 A ERAVT 4.82 67.2
323 472 I VI 2.9 44.7
324 473 Y NY 1.69 27.7
325 474 C AC 2.4 36.7
345 492 E NLSPTED 7.29 84.2
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346 493 P DEPTHAKG 8.01 88.7
347 494 T AGSCTNKDV 12.92 97.4
348 495 D D 1 19.0
349 496 Q QEDTKA 7.63 86.8
350 497 D DQEINKTVA 9.16 91.6
351 498 F LF 2.2 33.1
352 499 Y YFC 3.74 55.3
353 500 Q KERQTASGD 10.65 95.2
354 501 K MNKQERA 7.42 85.5
355 502 F F 1 19.0
356 503 A STPAN 6.29 78.1
357 504 T LTS 3.26 49.8
358 505 G TVMG 4.27 62.4
359 506 S IVSCANT 6.79 79.7
360 507 V .SV 13.02 100.0
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APPENDIX 2 
List of oligonucleotide primers  
Mutant Primer pair sequences 
GRK5 [NM_005308] 
F36A (+) 5’-TGGAAAGAAATCCTGAAGGCCCCTCACATTAGCCAGTGT (-) 5’-ACACTGGCTAATGTGAGGGGCCTTCAGGATTTCTTTCCA 
P37A (+) 5’-GAAATCCTGAAGTTCGGCTCACATTAGCCAGTGT (-) 5’-ACACTGGCTAATGTGAGCGAACTTCAGGATTTC 
H38A (+) 5’-GAAATCCTGAAGTTCCCTGCCATTAGCCAGTGTGAAGAC (-) 5’-GTCTTCACACTGGCTAATGGCAGGGAACTTCAGGATTTC 
C42A (+) 5’-CCTCACATTAGCCAGGCTGAAGACCTCCGAAGG (-) 5’-CCTTCGGAGGTCTTCAGCCTGGCTAATGTGAGG 
P61A (+) 5’-TTATGTGACAAGCAGGCAATCGGGAGGCTGCTT (-) 5’-AAGCAGCCTCCCGATTGCCTGCTTGTCACATAA 
I62A (+) 5’-TGTGACAAGCAGCCAGCCGGGAGGCTGCTTTTC (-) 5’-GAAAAGCAGCCTCCCGGCTGGCTGCTTGTCACA 
L66A (+) 5’-CCAATCGGGAGGCTGGCTTTCCGGCAGTTTTGT (-) 5’-ACAAAACTGCCGGAAAGCCAGCCTCCCGATTGG 
R68A (+) 5’-GGGAGGCTGCTTTTCGCGCAGTTTTGTGAAACC (-) 5’-GGTTTCACAAAACTGCGCGAAAAGCAGCCTCCC 
Q69A (+) 5’-AGGCTGCTTTTCCGGGCGTTTTGTGAAACCAGG (-) 5’-CCTGGTTTCACAAAACGCCCGGAAAAGCAGCCT 
D85A (+) 5’-TACATTCAGTTCCTGGCCTCCGTGGCAGAATAT (-) 5’-ATATTCTGCCACGGAGGCCAGGAACTGAATGTA 
F166A (+) 5’-TATCTGGACAGCATGGCTTTTGACCGCTTTCTC (-) 5’-GAGAAAGCGGTCAAAAGCCATGCTGTCCAGATA 
R169A (+) 5’-GACAGCATGTTTTTTGACGCCTTTCTCCAGTGGAAGTGG (-) 5’-CCACTTCCACTGGAGAAAGGCGTCAAAAAACATGCTGTC 
Q172A (+) 5’-TTTGACCGCTTTCTCGCGTGGATGGATTGGGAA (-) 5’-TTCCCAATCCATCCACGCGAGAAAGCGGTCAAA 
W173A (+) 5’-GACCGCTTTCTCCAGGCGAAGTGGTTGGAAAGG (-) 5’-CCTTTCCAACCACTTCGCCTGGAGAAAGCGGTC 
L176A (+) 5’-CTCCAGTGGAAGTGGGCGGAAAGGCAACCGGTG (-) 5’-CACCGGTTGCCTTTCCGCCCACTTCCACTGGAG 
P510A (+) 5’-GGCTCTGTGTCCATCGCATGGCAAAACGAGATG (-) 5’-CATCTCGTTTTGCCATGCGATGGACACAGAGCC 
E514A (+) 5’-ATCCCATGGCAAAACGCGATGATAGAAACAGAA (-) 5’-TTCTGTTTCTATCATCGCGTTTTGCCATGGGAT 
E517A (+) 5’-CAAAACGAGATGATAGCAACAGAATGCTTTAAG (-) 5’-CTTAAAGCATTCTGTTGCTATCATCTCGTTTTG 
T518A (+) 5’-AACGAGATGATAGAAGCAGAATGCTTTAAGGAG (-) 5’-CTCCTTAAAGCATTCTGCTTCTATCATCTCGTT 
Q172A-L176A (+) 5’-CTCGCGTGGAAGTGGGCGGAAAGGCAACCGGTG (-) 5’-CACCGGTTGCCTTTCCGCCCACTTCCACGCGAG 
E104K (+) 5’-CTGGGAGAGAAAGGGAAGAAAATTATGACCAAGTACCTC (-) 5’-GAGGTACTTGGTCATAATTTTCTTCCCTTTCTCTCCCAG 
R304H (+) 5’-TTAGAAGACCTCCACCATGAGAACACCGTCTAC 
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(-) 5’-GTAGACGGTGTTCTCATGGTGGAGGTCTTCTAA 
G439E (+) 5’-GGCTGCCAGGAGGAGGAGGCTGCAGAGGTCAAG (-) 5’-CTTGACCTCTGCAGCCTCCTCCTCCTGGCAGCC 
S484A (+) 5’-GACATCGAGCAGTTCGCCACTGTGAAGGGCGTCAAT (-) 5’-ATTGACGCCCTTCACAGTGGCGAACTGCTCGATGTC 
T485A (+) 5’-GACATCGAGCAGTTCTCCGCTGTGAAGGGCGTCAAT (-) 5’-ATTGACGCCCTTCACAGCGGAGAACTGCTCGATGTC 
S484A-T485A (+) 5’-GACATCGAGCAGTTCGCCGCTGTGAAGGGCGTCAAT (-) 5’-ATTGACGCCCTTCACAGCGGCGAACTGCTCGATGTC 
GRK6 [NM_001004106] 
Y166A (+) 5’-TACCTCGACAGCATCGCCTTCAACCGTTTCCTG (-) 5’-CAGGAAACGGTTGAAGGCGATGCTGTCGAGGTA 
L66A-R69A (+) 5’-CGGCTGGCCTTCCGAGCGTTCTGTGCCACGAGG (-) 5’-CCTCGTGGCACAGAACGCTCGGAAGGCCAGCCG 
Q172A-W173A (+) 5’-AACCGTTTCCTGGCGGCGAAGTGGCTGGAAAGG (-) 5’-CCTTTCCAGCCACTTCGCCGCCAGGAAACGGTT 
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